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Summary 
Extracellular signals are translated and amplified via cascades of serially switched protein kinases, 
MAP kinases (MAPKs). One of the MAP pathways, the classical RAS/RAF/MEK/ERK pathway, 
transduces signals from receptor tyrosine kinases and plays a central role in regulation of cell 
proliferation. RAF kinases (A-, B- and C-RAF) function atop of this cascade and convert signals 
emanating from conformational change of RAS GTPases into their kinase activity, which in turn 
phosphorylates their immediate substrate, MEK. Disregulated kinase activity of RAF can result in 
tumor formation, as documented for many types of cancer, predominantly melanomas and thyroid 
carcinomas (B-RAF).  
A-RAF is the least characterized RAF, possibly due to its low intrinsic kinase activity and 
comparatively mild phenotype of A-RAF knockout mice. Nevertheless, the unique phenotype of    a-
raf -/- mice, showed predominantly neurological abnormalities such as cerebellum disorders, 
suggesting that A-RAF participates in a specific process not complemented by activities of B- and C-
RAF. 
Here we describe the role of A-RAF in membrane trafficking and identify its function in a specific 
step of endocytosis. This work led to the discovery of a C-terminally truncated version of A-RAF, 
AR149 that strongly interfered with cell growth and polarization in yeast and with endocytosis and 
actin polymerization in mammalian cells. As this work was in progress two splicing isoforms of A-
RAF, termed DA-RAF1 and DA-RAF2 were described that act as natural inhibitors of RAS-ERK 
signaling during myogenic differentiation (Yokoyama et al., 2007). DA-RAF2 contains the first 153 
aa of A-RAF and thus is nearly identical with AR149. AR149 localized specifically to the recycling 
endosomal compartments as confirmed by colocalization and coimmunoprecipitation with ARF6. 
Expression of AR149 interferes with recycling of endocytosed transferrin (Tfn) and with actin 
polymerization. The endocytic compartment, where internalized Tfn is trapped, was identified as 
ARF6- and RAB11- positive endocytic vesicles. We conclude that the inhibition of Tfn trafficking in 
the absence of A-RAF or under overexpression of AR149 occurs between tubular- and TGN-
associated recycling endosomal compartments. siRNA-mediated depletion of endogenous A-RAF or 
inhibition of MEK by U0126 mimic the AR149 overexpression phenotype, supporting a role of A-
RAF regulated ERK signalling at endosomes that is controlled by AR149 and targets ARF6.  
Our data additionally suggest EFA6 as a partner of A-RAF during activation of ARF6. The novel 
findings on the A-RAF localization and the interaction with ARF6 have led to a new model of A-
RAF function were A-RAF via activation of ARF6 controls the recycling of endocytic 
vesicles.Endocytosis and rapid recycling of synaptic vesicles is critically important for the 
physiological function of neurons. The finding, that A-RAF regulates endocytic recycling  open a 
new perspective for investigation of the role of A-RAF in the nervous system. 
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Zusammenfassung 
Extrazelluläre Signale werden über eine Serie von nacheinander geschalteten Proteinkinasen, den 
MAP-Kinasen (MAPK) weitergeleitet und multipliziert.  Einer der MAPK-Signalwege, der 
RAS/RAF/MEK/ERK-Signaltransduktionsweg, leitet Signale von Tyrosinkinaserezeptoren weiter 
und spielt eine zentralle Role in der Regulation der Zellproliferation. RAF Kinasen (A-, B-, und C-
RAF) stehen am Anfang der Kaskade. Sie wandeln die signalbedingte strukturellen Änderungen der 
RAS-GTPase in ihre Kinaseaktivität um und phosphorylieren ihr direktes Substrat, MEK. Eine 
Störung in der Regulation der Kinaseaktivität des RAF-Proteins kann zur Tumorbildung führen, wie 
es bei vielen Krebsarten, vor allem Melanom und Schilddrüsenkarzinom (B-RAF), dokumentiert ist. 
A-RAF ist die bislang am wenigsten charakterisierte RAF-Kinase, möglicherweise  aufgrund sihrer 
nidrigen intrinsischen Kinaseaktivität. Weiterhin weist die A-RAF defficiente Maus einen relativ 
milden hauptsächlich neuronalen Phänotyp auf, der sich unter anderem auch in einer Fehlfunktion des 
Cerebellums manifestiert. Dieser einzigartige Phänotyp weist darauf hin, dass eine Reihe zellulärer 
Prozesse spezifisch durch A-RAF und nicht durch aktiveren B- und C-RAF vermittellt wird. 
Im Rahmen dieser Doktorarbeit wurde die Rolle des A-RAF-Proteins im intrazellulären 
Membrantransport analysiert und eine spezifische A-RAF Funktion by endozytotischen Prozessen 
identifiziert. Diese Arbeit führte zur Entdeckung einer C-terminal verkürtzten  Form von A-RAF, 
AR149, welche das Wachstum und  die Polarisation von Hefezellen   beeinträchtigt. In 
Säugetierzellen wirkt AR149 störend auf die Endozytose und die Aktinpolymerisation. Während des 
Entstehungsprozesses dieser Studie, wurden parallel zwei Spleißisoformen des A-RAF-Proteins, DA-
RAF1 und 2, publiziert, die als natürliche Inhibitoren des RAS-RAF-MEK-ERK-Signalwegs in der 
myogenen Differenzierung agieren (Yokoyama et al., 2007). DA-RAF2 beinhaltet die ersten 153 
Aminosäuren des A-RAF Proteines und ist damit fast identisch mit AR149. Eigene Kolokalisierung- 
und Koimmunopräzipitationsexperimente mit ARF6 weisen darauf hin, dass AR149 spezifisch in 
ARF6-positiven Recycling-Endosomen lokalisiert ist. Expression des AR149 Proteins bechindert das 
Recycling von endozytiertem Transferrin und die Aktin Polimerisation. Die endosomalen 
Kompartimente in denen internalisiertes Transferrin gefangen vor liegt, konntenals ARF6- und 
RAB11-positive endozytotische Vesikeln characterisiert werden.  Diese Ergebnisse lassen auf eine 
durch A-RAF Überexpression bzw. durch die Abwesenheit an A-RAF vermittelte Blokade des 
intrazellulären Transferrintransportes zwischen den tubulären- und Trans-Golgi-Netzwerk-assoziirten 
endosomalen Recycling-Kompartimenten schließen. Inhibierung der endogenen A-RAF-Expression 
durch siRNA oder Hemmung der MEK-Aktivität durch U0126 haben den selben Effekt wie AR149.  
Auf der Basis dieser Ergebnisse wird ein neues Modell für die Rolle der A-RAF regulierten ERK 
Signallwirkung auf Endosomen vorgestellt, bei dem das Zielprotein die ARF6 GTPase durch 
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AR149/DA-RAF2 negativ reguliert wird. Daruber hinaus deuten unsere Daten darauf hin, dass EFA6, 
ein GEF-Faktor von ARF6, als Kooperationspartner von A-RAF bei der ARF6-Aktivierung fungiert. 
Endocytose und das schnelle Recycling von synaptischen Vesikeln ist von besonderer Bedeutung 
für die Funktion von Neuronen. Aus dem Befund, dass A-RAF ein Regulator des endocytotischen 
Recyclings ist ergibt sich dacher eine neue Perspektieve für die Untersuchung der A-RAF Funktion 
im Nervensystem. 
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1. Introduction 
 1.1 The RAF protein family     
  1.1.1 General characteristics of RAF proteins 
RAF protein kinases were originally identified as viral oncogenes (Jansen et al., 1984; Rapp et al., 
1983) encoded in murine and avian retroviruses. RAF proteins are serine/threonine kinases (Mark and 
Rapp, 1984; Moelling et al., 1984) that mediate transduction of extracellular mitogenic signals from 
activated Ras GTPases at the plasma membrane to a MAP kinase module (RAF-MEK-ERK), the 
mitogenic cascade (reviewed in (Daum et al., 1994)). This process leads to signal amplification and 
diversification via phosphorylation of dozens of different cytoplasmic and nuclear substrates by 
activated ERK. As a result, complex physiological responses to growth factor stimulation take place 
at multiple cellular levels (Fig1-1).  
 
Figure 1-1. The mitogen pathway.  
 
Phylogenetically, the appearance of RAF kinases has been linked to the evolution of multicellular 
organisms. The growing complexity of metazoans is accompanied by the appearance
of isoforms and functional specialization of RAF kinases. Arthropod genomes contain only a single 
RAF gene, whereas vertebrates have refined RAF signalling and employ three isoforms that target 
ERK signalling to different subcellular compartments (Rapp et al., 2006). From the three human 
RAF isoforms A-, B- and C-RAF, B-RAF is the clothest related one to other eukaryotic RAFs. This 
leads to the conclusion that B-RAF from evolutionary point of view is the most ancient isoform. 
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  1.1.2  B-RAF characterization 
The B-raf gene is located on chromosome 7p34 and encodes proteins in the molecular weight 
range between 69 and 100 kDa, which are generated by alternative splising. At least 10 B-RAF 
isoforms were found in adult mouse tissues (Barnier et al., 1995). The  B-RAF isoforms are 
differently distributed in the tissues, for example isoforms encoded by exon 10 are specifically 
expressed in neural tissues. In general B-RAF was detected at highest levels in neural tissue 
(especially in midbrain, dorsal spinal crod and neuroretina) and at high level in ovaries and testis, 
whereas expression in kidney, spleen, thymus, liver and heart was lower, ranging from intermediate 
expression level to barely detectable in muscle. 
B-RAF knock out mice show overall growth retardation and die in mid-gestation (between E10.5 
and E12.5) due to vascular defects caused by massive apoptosis of epithelial cells and some 
neurological abnormalities such as disturbed growth and differentiation of the neuroepitelium 
(Wojnowski et al., 1997). Later work with the different combinations of C- and B-RAF knock out 
mutants shows that B- and C-RAF may cooperate in the activation of MAP kinase (Wojnowski et 
al., 2000). 
Sensory neurons and motoneurons from the B-RAF deficient mice do not survive in primary cell 
culture upon neurotrophic factors stimulation, possibly due to the upregulation of IAPs (Wiese et 
al., 1999; Wiese et al., 2001). However, recent work shows that A-RAF expression under the b-raf 
promoter rescues B-RAF-deficient embryos from endothelial apoptosis and allows them to survive 
until after mid-gestation. A fraction of these late-stage embryos survived to adulthood. Histological 
analysis demonstrated that A-RAF can substitute for B-RAF in mediating growth factor-dependent 
survival. However, A-RAF is unable to restore neuron migration and dendrite formation (Camarero 
et al., 2006).  
Biochemically, B-RAF is the most active kinase. Mutations within the B-raf gene were found to 
be assotiated with human cancer (Davies et al., 2002). Specifically somatic mutations in B-RAF are 
associated with 60% of malignant melanomas and occur with moderate to high frequency in 
colorectal (Rajagopalan et al., 2002), ovarian (Singer et al., 2003), and papillary thyroid carcinomas 
(Brose et al., 2002; Cohen et al., 2003). 
  
 1.1.3  C-RAF characterization 
The C-raf gene is located on chromosome 3p25 and encodes a 75 kDa protein. Till now, no C-
RAF splicing isoforms have been identified. Earlier studies on the expression pattern of RAF 
showed that the C-RAF transcript was ubiquitously expressed in mouse, with highest level in 
striated muscle, cerebellum and fetal brain. (Barnier et al., 1995) 
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C-RAF knock out mice, like B-RAF deficient mice, show general growth retardation and also 
die in mid-gestation. In contrast to B-RAF, a different spectrum of tissues are affected 
encompassing lungs, skin and liver. In an inbred background, mice with abrogated C-RAF 
expression die between E10.5 and E12.5, while in an outbred background they survive until P0, but 
die within hours after birth, because their lungs fail to inflate (Mikula et al., 2001; Wojnowski et al., 
1998). C-RAF-/- fetal livers were hypocellular, contained numerous  apoptotic cells. Similarly, the 
appoptotic index in primary fibroblast and haematopoietic cell cultures  was increased (Mikula et 
al., 2001). 
These data indicate an essential role of C-RAF in counteracting apoptosis. This is further 
supported by more recent work, which identified new substrates of C-RAF such as XIAP, a potent 
inhibitor of apoptosis (Dogan et al., 2008; Tian et al., 2006) and eukaryotic elongation factor 1A 
(eEF-1a) (Lamberti et al., 2007). In both cases C-RAF activity mediated stabilisation of these 
proteins and induced their prosurvival activity. 
Interestingly, C-RAF was found to be selectively bound with mitochondria, one of the main 
platforms for apoptosis regulation. In this context C-RAF found to have an influence on 
mitochondrial shape and cellular distribution (Galmiche et al., 2008). Recently it was also shown 
that C-RAF controlls mitochondrial Ca 2+ homeostasis through counteracting of ROS production 
(Kuznetsov et al., 2008).  
C-RAF was found to be amplified in different lung cancer cell lines and its expression level is a 
critical parameter in lung tumor development (Kerkhoff et al., 2000).  
 
 1.1.4  A-RAF characterization 
The A-raf gene is located on the X chromosome at position Xp11.2 and encode a 68 kDa protein. 
Recently two A-RAF splicing isoforms were described, DA-Raf1 and DA-Raf2, which are 
generated by alternative splicing of the A-raf pre-mRNA (Yokoyama et al., 2007). The amino acid 
sequences of DA-Raf2 (17 kDa) and DA-Raf1 (23 kDa) correspond to the first N-terminal 154 and 
186 amino acids of A-RAF respectively, which contain the CR1 but lack the CR2 and the CR3 
domains, the regions within RAF which sequences are conserved between RAF isoforms.   
The human A-raf promoter region is unique as it contains three potential glucocorticoid response 
elements GRE-1, GRE-2, GRE-3 (Lee et al., 1996). GRE-2 and GRE-3 motifs were shown to 
interact with the glucocorticoid receptor DNA binding domain (DBD) in vitro. The fact that 
CRE1,2,3 are conserved sequences in the A-RAF promoters of rat, mouse and human suggests A-
RAF exerts specific functions that are distinct from B- and C-RAF.  
With this high expression levels of A-raf were observed in steroid-hormone-responsive tissues 
such as epididymis and ovary (Storm et al., 1990). The expression was found to be hormone-
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dependent (Winer and Wolgemuth, 1995). The later research of A-RAF tissue distribution at 
mRNA and protein levels supported and refined this view. It was found that the distribution of full 
length A-RAF mRNA shows the highest level in urogenital tissue, lower levels were observed in 
thymus, spleen, pancreas, lung and cerebellum, expression was barely detectable in cerebral cortex 
and skeletal muscle. This information was refined by X-Gal staining of A-RAF through generation 
of transgenic mice expressing the β-gal reporter gene controlled by the A-raf promoter. 
Intriguingly, in the cerebellum A-RAF was found to be located only in the cell body of Purkinje 
cells, but not in the molecular or granular layers (Luckett et al., 2000). 
In contrary to A-RAF full length protein expression, both splicing isoforms; DA-RAF1,2, were 
highly expressed in brain, heart and skeletal muscle and less expressed in urogenital tissue, liver 
and spleen (Yokoyama et al., 2007). 
The A-RAF knock out mice phenotype was milder compared to that of B- and C-RAF. The 
animals survived until adulthood (Pritchard et al., 1996). Again background dependent differences 
were observed. On a predominantly C57 BI/6 genetic background, A-RAF deficient mice developed 
neurological and intestinal abnormalities and died between 7 and 21 days post-partum. They were 
in general smaller and showed progressive wasting, despite normal feeding, suggesting that they 
either had a metabolic defect in sufficient absorbation of nutrients, wich may reflect the 
involvement of A-RAF in M2PK regulation (Mazurek et al., 2007). A-RAF deficient animals bread 
on 129/OLA background survived to adulthood, are fertile, do not display obvious intestinal 
abnormalities, but have a subset of neurological defects. 
The urogenital tract, spleen and thymus, which express high level of A-Raf mRNA (Storm et al., 
1990), showed only generalized reduction in size, but normal morphology and architecture. 
The main intestinal defect obserwed in A-raf-deficient mice was  the megacolon. This was similar 
to aganglionic megacolon (Hirschsprung disease), which is associated with the absence of enteric 
ganglia and results in intestinal blockade (reviewed in (Amiel et al., 2008)). Although no 
morphological changes were detected in tissue architecture and distribution of enteric neurons in 
colon of A-raf –deficient animals, it was proposed that in this case function of enteric neurons could 
be affected without histopathological manifestation. It is conceivable that A-RAF has a crucial role 
in function of enteric neurons, so that lost of A-RAF mimics the phenotype of absence of enteric 
ganglia. 
The neurological abnormalities are constricted to classical cerebellum disorders: abnormal 
movement (ataxia) and affected proprioception, continuous tremor and a rigidity of their 
musculature. However, despite intensive investigations, none histological abnormalities were 
observed in the cerebellum of A-RAF deficient mice. This data, together with localisation of A-
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RAF to Purkinje cells (see above), clearly suggested that A-RAF may be crucial for normal function 
of Purkinje cells without affecting their survival (Pritchard et al., 1996). 
In summary the phenotype of the A-RAF knock out mouse demonstrated the involvement of A-
RAF in metabolic processes and neuronal cell functions. 
 
1.1.5 Structure of RAF proteins 
The three RAF isoforms share common structural features comprising three conserved regions, 
CR1, CR2, CR3. The N-terminal CR1 encompasses the RAS binding domain (RBD) and the 
cysteine-rich domain (CRD), CR2 contains a conserved 14-3-3 binding motif and the C-terminally 
located CR3 encodes a kinase domain (Fig.1-2). 
The RAF kinase can functionally be divided into two parts: the regulatory part (CR1+CR2) and 
the kinase domain (CR3). The N-terminal part contains predominantly negatively regulating 
phosphorylation sites. It mediates the initiation of activation steps via RBD. CRD domain presents 
lipid binding domain which determines different localization of RAF isoforms to specific lipid 
membranes. Through negatively regulated 14-3-3 phosphorylation site in CR2-domain the RAF 
conformation in signalling complex is determined. 
Deletion of CR1+CR2 leads to a constitutively active kinase, also reported to as RAF-BXB 
(Bruder et al., 1993). B-RAF-BXB is the only RAF molecule that has sofar been crystallized (Wan 
et al., 2004). Its atomic structure shows a bilobal architecture: consisting of a N- and C-lobe. The N-
lobe contains an N-region, P-loop and the glycin-rich ATP-binding site, whereas the C-lobe 
contains the substrate binding site and the so called activation segment. These two lobes build a 
deep hydrophobic pocket. Conformational changes of this pocket determine the activation state of 
the kinase.  
   
Figure 1-2. Schematic diagram of domain structure of RAF proteins 
Lipid binding domains are indicated by yellow boxes. 
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1.2 Regulation of RAF kinase activity 
1.2.1 Activation of RAF kinases by the RAS family of small GTPases 
The RAS protein family comprises a group of structurally and functionally conserved small GTP-
binding proteins, such as H-RAS, K-RAS, R-RAS, RAL, RAP and RHEB (reviewed in (Hancock, 
2003; Kinbara et al., 2003) ). RAS proteins are small GTPases that operate as molecular switches 
linking exstracellular stimuli to diverse biological outcomes such as cell growth, proliferation and 
differentiation. 
 Ras proteins cycle between GTP-bound and GDP-bound forms. The kinetics of GTP hydrolysis 
and GDP dissociation are catalysed by two classes of auxiliary proteins: GAPs (GTPase-activating 
proteins) and GEFs (guanidine-nucleotide exchange factors), respectively. GEFs promote the release 
of bound GDP and the capture of a new GTP molecule, which activates RAS-family proteins. GAPs 
stimulate the low intrinsic GTPase activity, resulting in de-activation of RAS proteins.The receptor 
interface for effectors is provided by so called switch regions (switch І, switch ІІ and the P-loop) 
within  RAS proteins. The P-loop encompasses the nucleotide binding site and coordinates the 
phosphate binding, whereas the switch І and ІІ regions form mobile effector binding surface RAS 
proteins (H-, N- and K-RAS) have two structural domains: the highly conserved amino-terminal 
catalytic domain (1-165 aa) and a carboxy-terminal sequence (165-188/9), called hypervariable 
region (HVR). The HVR contains two anchor elements common for RAS proteins: the CAAX motif 
and a second motif which comprises a single palmitoylation site (C181) in N-RAS, two 
palmitoylation sites (C181, C184) in H-RAS and a polybasic domain of six contiguous lysine 
residues in K-RAS. These motifs function as a platform for posttranslational modifications which are 
critical for RAS protein trafficking and their isoform specific membrane microdomain localization.  
The activation of RAS starts with binding of ligands (growth factors) to their receptor tyrosine 
kinase (RTK) at the plasma membrane (Fig.1-1). This event recruits Son-of-sevenless (Sos) protein, a 
RAS GEF, to the plasma membrane. In succession a complex with the adaptor proteins growth-factor 
receptor bound protein 2 (Grb2) and SRC-homology-2 domain containing (SHC). Sos, promotes the 
capture of a new GTP molecule to RAS at the plasma membrane. This switches RAS to its “on” 
conformation. In this open active form RAS binds to the RAS-binding domain (RBD) of RAF and 
forms a secondary interaction surface with the cysteine-rich domain (CRD) located in CR1 
(Wittinghofer and Nassar, 1996). RAF is recruited to the plasma membrane and initiates several 
phosphorylation events within the RAF kinase domain. 
The human RAS isoforms bind to the RBD with different affinity (Weber et al., 2000). A recent 
study showed that C-RAF only binds farnesylated (membrane bound) H-RAS, whereas B-RAF binds 
with similar affinity to both farnesylated and non-farnesylated forms. It has been concluded, that B-
RAF does not necessarily need to be recruited to the membrane for RAS binding, because its 
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extended N-terminus causes more open protein conformation, than that of C-RAF (Fischer et al., 
2007). 
RAS signalling may not be restricted to the plasma membrane, but also may occur at 
endomembranes, such as Golgi apparatus and endoplasmic reticulum (Chiu et al., 2002) (Rocks et al., 
2005). Indeed there is strong evidence that RAS transits through the endosomal compartment in its 
active state (Burke et al., 2001; Jiang and Sorkin, 2002; Rizzo et al., 2001). 
 
1.2.2 RAF regulation by phosphorylation 
Phosphorylation of RAF kinases is a very important part of signal transduction processes, because it 
regulates not only their activation state, but also their docking to several interaction partners which in 
turn  impacts the sub-cellular localisation of RAF proteins. 
The best investigated RAF isoform with regard to phosphorylation is C-RAF. In general, the N-
terminus of RAF comprises inhibitory phosphorylation sites, while the C-terminus – horbors 
activatory sites.  Three phosphorylation sites have been identified At the N-terminal region            of 
C-RAF: 
i) S43 - seems to sterically hinder C-RAF binding to RAS (Wu et al., 1993); 
ii) S233 - forms the core of the third  14-3-3-binding site (Dumaz and Marais, 2003); 
iii) S259 - internal 14-3-3 binding site, common for all three RAF isoforms (Dumaz and 
Marais, 2003; Ory et al., 2003). 
These three phosphorylation sites contribute to C-RAF inhibition by PKA (Dumaz and Marais, 
2003), S259 can be also phosphorylated by AKT/PKB (Zimmermann and Moelling, 1999). 
iv) T268 - represent the residue homologous to T372 in B-RAF, an autophosphorylation site 
(Morrison et al., 1993); 
v) S289, S296, S301 - are sites for ERK-mediated inhibitory feedback phosphorylation 
(Balan et al., 2006; Dougherty et al., 2005; Hekman et al., 2005). These sites are also 
present in B-RAF. For A-RAF new ERK feedback phosphorylation sites 
(T253/S257/S259) were identified in the so called IH-segment, which may, in contrast 
to B-and C-RAF, positively regulate A-RAF activity (Baljuls et al., 2008). 
The C-terminus of RAF includes the kinase domain. Most of the phosphorylation sites in this region 
are activating: 
i) S621 - C-terminall 14-3-3 binding site, is essential for activation by stimulatory factors 
(Mischak et al., 1996; Yip-Schneider et al., 2000); 
ii) S338 - is located in N-region. Its phosphorylation is required for C-RAF activation (Diaz 
et al., 1997). This site is probably targeted by PAK 1, PAK2 kinase (King et al., 2001) 
and  phosphatidylinositol 3-kinase (PI3-kinase) (Sun et al., 2000). In B-RAF the 
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homologous site S446 is constitutively phosphorylated and therefore possible 
responsible for high basal B-RAF activity (Hekman et al., 2002). 
iii) Y340/341 - phosphorylation are necessary for C-RAF activation  (Marais et al., 1995; 
Marais et al., 1997). These sites are targeted by SRC-family kinases in cooperation with 
S338 phosphorylation by PAK (King et al., 2001); homologous sites are present in A-
RAF. This site are substituted by phosphomimetic aspartates in B-RAF, that lead to 
constitutive phosphorylation of S446. The analogous site in A-RAF, S299, was not 
considered as regulatory site. Recent work by Baljuls et al. (2007) showed, that the 
unique Y296 in A-RAF is the major determinant of the low activating potency of A-
RAF. 
   
1.2.3 Regulation of RAF signalling by scaffold proteins 
14-3-3 - adaptor proteins participate in the regulation of a number of crucial processes: metabolism, 
signal transduction, protein trafficking, cell cycle control etc. (reviewed in (Aitken, 2002; 
Dougherty and Morrison, 2004)). Seven mammalian isoforms of 14-3-3 proteins have been 
identified so far. The association of 14-3-3 with client proteins occurs through defined high 
affinity peptide motifs, two of which (RSXpSXP and RXXXpSXP) are  recognized by all 
14-3-3 isoforms. Morrison et al. identified three basal phosphorylation sites in C-RAF: the 
serine residues at positions 43, 259 and 621 (Morrison et al., 1993). Two of these sites 
(serine 259 and 621) are involved in binding of 14-3-3 proteins to C-RAF. Phosphorylation 
of serine 621 seems to be essential for C-RAF activation, since the mutation of serine 621 to 
alanine resulted in a RAF protein that could no longer be activated by growth factor 
stimulation (Hekman et al., 2004; Tzivion et al., 1998). In contrast, exchange of serine 259 
by alanine or aspartic acid resulted in enhancement of kinase activity, indicating that 
phosphorylation of serine 259 is inhibitory (Zimmermann and Moelling, 1999). 
Furthermore, the binding of 14-3-3 proteins to the C-terminal conserved site has been found 
to be differentially and dynamically regulated (Hekman et al., 2004). 
KSR - kinase suppressor of RAS - has a high homology to RAF proteins, but its kinase domain has 
mutations in key residues that are essential for catalytic activity in other protein kinases. 
Only one work showed that KSR has kinase activity and works not only as a scaffold protein 
(Kolesnick and Xing, 2004). As a scaffold for mitogen signalling, KSR binds directly to 
RAF, MEK, ERK and other scaffolds (CNK, 14-3-3) thereby tethering these components 
together and ensuring a fast and selective response (reviewed in (Kolch, 2005)). 
CNK - conector enchancer of KSR - was identified as an enhancer of a dominant negative 
phenotype caused by the isolated KSR kinase domain. CNK has no catalytical motifs, but 
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contains several protein interaction domains, contributing to its function as a multivalent 
adaptor protein (Kolch, 2005). 
Prohibitin - an ubiquitously expressed protein functions in cell cycle and apoptosis regulation. 
Recent work shows that prohibitin targets C-RAF to the cell membrane through direct 
interaction (Rajalingam et al., 2005).  
Hsp90 - heat shock protein 90 - an ubiquitous chaperone has an important role in assisting and 
 maintaining the folding of many signaling proteins including C-RAF. Drugs, such as 
 geldanamycin and derivatives, that prevent the interaction of Hsp90 with client proteins, 
 lead among others to the ubiquitination and degradation of C-RAF (Blagosklonny, 2002). 
MP1 - MEK partner 1 - is a widely expressed small scaffold protein that aids MEK1 binding to 
ERK1 and enhances their activity. MP1 forms a tight heterodimer with p14, a protein that 
targets MP1 and its binding partners to late endosomes. (Schaeffer et al., 1998; Teis et al., 
2002).  
 
1.2.4 Heterodimerisation of RAFs 
The study of oncogenic mutations of B-RAF in cancer cells reviewed that: three out of 22 
analyzed B-RAF mutants had reduced kinase activity in vitro, but lead to increased ERK activity in 
vivo. Subsequent analysis showed that the mutants with impaired kinase activity stimulate MEK by 
stimulating endogenous C-RAF activity, possibly via an allosteric or transphosphorylation 
mechanism. RAS induces wild type B-and C-RAF complex formation. In the case of above 
mentioned B-RAF mutants, the heterodimerization occurs in the cytosol independently of RAS, 
leading to oncogenic transformation (Wan et al., 2004). 
 
1.2.5 Lipids, membranes and RAF activation. 
The Singer-Nicholson fluid mosaic concept postulated the biomembranes as the luid structures in 
which lipids and integral proteins are arranged in a mosaic manner. Recent work added new insight 
to this concept. It could be shown, that lipids exist in several phases in bilayer's model system: gel, 
liquid ordered and liquid disordered states, depending a fluidity (reviewed in (Brown and London, 
1998)). The different components of biological membranes, such as lipids and proteins, coexist, 
interact with and influence each other. 
Lipid rafts - were originally defined biochemically as detergent-resistant membrane (DRM) 
fractions, later named rafts. Rafts are proposed to be highly dynamic, submicroscopic assemblies 
that float freely within the liquid disordered bilayer in the cell membrane. Sphingolipids and 
cholesterol play a crucial role in the assembly of these domains (Simons and Vaz, 2004). Clustering 
of separate rafts exposes proteins to a new membrane environment. Rafts are shown to be enriched 
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in specific enzymes, such as kinases, phosphotases, palmitoylases and depalmitoylases (Simons and 
Toomre, 2000).  
The cell surface invaginations called caveolae are formed from lipid rafts by polymerisation of 
caveolins - hairpin-like palmitoylated integral membrane proteins that tightly bind cholesterol 
(Smart et al., 1999). Caveolae formation is actually the initial step of one type of endocytosis, called 
caveolae-dependend endocytosis. 
Mitogenic signal transduction is sensitive to depletion of caveolins. H-RAS is palmitoylated and 
therefore, unlike K-RAS, targeted raft microdomains. Release of H-RAS·GTP from rafts is 
necessary for efficient activation of RAF (Prior et al., 2001; Roy et al., 1999).  
Phosphatidylserine (PS) - is a major phospholipic component of all biological membranes. Like 
other phospholipids, PS contains a diglyceride, a phosphate group, and a simple organic molecule, 
in this case serine. PS act as principal physiological co-factor for protein kinase C (PKC) activation. 
It works in cojunction with diacylglycerol and phorbol ester (Hannun et al., 1986) through binding 
to the cysteine-rich domain of PKC (Mosior et al., 1996). The CR1 region of C-RAF kinase 
contains a zinc-coordinating motif, which is the binding site for PS. The cluster of amino acids 
R143, K144, and K148 appeared to be critical for interaction with PS, which binds predominantly 
via electrostatic interactions, driven by a cluster of basic amino acid residues (Improta-Brears et al., 
1999; Mott et al., 1996).  
Phosphatidic acid (PA) - is the acidic form of phosphatidate, a common phospholipid which is a 
major constituent of cell membranes. PA is the smallest of the phospholipids. Activated 
phospholipase D (PLD) catalyses the hydrolysis of phosphatidylcholine to generate PA. 
Due to its physical properties PA can influence membrane curvature and therefore participates in 
both: cell und vesicle fusion. Moreover, PA acts as a signalling lipid, recruiting cytosolic proteins to 
appropriate membranes. MAP kinase pathway stimulation by insulin is dependent on PLD 
activation and leading to the PA mediated C-RAF translocation to the plasma membrane (Rizzo et 
al., 1999) (Rizzo et al., 2000). C-RAF contains a PA-binding site (398-401aa), which is strongly 
conserved in all three RAF isoforms. Mutational analysis of this domain showed that the residues 
R398, K 399, and R401 are crucial for C-RAF binding to PA (Ghosh et al., 2003). These binding 
sites are necessary for C-RAF function. PA did, however, not activate C-RAF in vitro or in vivo. 
The primary function of PA is therefore to enhance the recruitment of C-RAF to the plasma 
membrane where other factors, such as RAS, lead to its activation. 
Thus RAF kinases are located in different lipid microdomains due to specific binding to membrane 
lipids. This specification seems vary between the three RAF isoforms and is changed upon 
activation/deactivation steps (Hekman et al., 2002).  
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Phosphatidylinositol-4,5-bisphosphate (PtdIns(4,5)P2  ) - is a minor phospholipid which 
contains an inositol ring, phosphorylated on position 4 and 5, which is aligned with phosphatidate. 
PtdIns(4,5)P2, a precursor of inositol-1,4,5-triphosphate (IP3) and diacylglycerol (DAG), comprises 
~1% of the total phospholipids in the eukariotic plasma membrane. Hydrolysis of PtdIns(4,5)P2 by 
phospholipase C (PLC) to the second messengers, IP3 and DAG, is a general and well defined 
response of cells to membrane receptor stimulation. It is now recognised that PtdIns(4,5)P2 are 
signalling molecules by themselves and can, by binding to unique phosphoinositide-binding sites, 
affect the activity and subcellular localization of many proteins, including several actin regulatory 
proteins, wide range of ion channels and phospholipase D (PLD) (reviewed in (Huang, 2007; Oude 
Weernink et al., 2007)). 
The micro-localisation of PtdIns(4,5)P2 in membrane is currently under discussion. Two concepts 
suggest that PtdIns(4,5)P2 is either localized to lipid rafts (Pike and Casey, 1996) or has specific 
PtdIns(4,5)P2 clustering (van Rheenen et al., 2005).  
The cellular distribution of PtdIns(4,5)P2 can be visualised via its high-affinity interaction with 
the pleckstrin homology (PH) domain of PLCδ tagged with green fluorescent protein (GFP-
PLCδ(PH)) (Falasca et al., 1998). Using GFP-PLCδ(PH) it was shown that PtdIns(4,5)P2 localizes 
to plasma membrane (PM) and to recycling tubular compartment in HeLa cells (Robertson et al., 
2006) and to highly dynamic, actin rich regions of PM (Tall et al., 2000) 
The synthesis of PtdIns(4,5)P2 by phosphoinositide 5-kinase (PIP5K) isoforms is tightly regulated 
by small GTP-ases. Although ARFs GTP-ases have been shown to stimulate PIP5K activity in 
vitro, in cells it is ARF6 that localizes with PIP5K at the PM (Honda et al., 1999).  
In regard to RAF proteins and PtdIns(4,5)P2, there is only one published study of all three RAF 
isoforms binding to phospholipids in vitro (Johnson et al., 2005). From these experiments it can be 
concluded that A-RAF, but not C- und B-RAF, binds specifically to PtdIns(4,5)P2 and that crucial 
binding domain is located to the N-terminus of A-RAF. 
 
1.2.6 Downstream targets of RAFs 
 The RAF kinases act as MAP kinase kinase kinases (MAPKKK), activating MEK (MAPKK), 
which in turn activates the MAP kinase ERK (Kyriakis et al., 1992).  
MEK (mitogen activated kinase kinase) has two isoforms MEK1 and MEK2, which are 
phosphorylated by RAFs on two serine residues S218, S222 of their activation segment – 
LIDSMANS. Mutation of these residues to glutamic acid resulted in constitutive active kinase – 
LIDEMANE. MEK phosphorylates its target, ERK, on two residues: T183 and a Y185 on its 
regulation segment (Payne et al., 1991; Robbins et al., 1993). 
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ERK (extracellular signal-regulated kinase) in mammals has two isoforms ERK1 (44 kD) and 
ERK2 (42 kD). ERK1/2 has a lot of different substrates, such as transcription factors: Elk1, c-fos 
and c-jun (reviewed in (Yoon and Seger, 2006)).  
Concerning this work, there is a significant evidence, that ERK1/2 is able to phosphorylate a GEF 
factor for RhoA, GEF-H1, enhance its activity and thus contribute to the activation of RhoA 
(Fujishiro et al., 2008) 
 
1.3 Endocytosis 
   1.3.1  Classification and structural units of endocytosis  
Endocytosis is a cellular process involving  the PM, by which macromolecules, membranes and 
particles are internalized. There are four main types of endocytosis: 
i) caveolar endocytosis; 
ii) clatrin-mediated endocytosis (CME);  
iii) macropinocytosis; 
iv) clathrin and caveolin-independend endocytosis 
v) phagocytosis. 
The endocytic pathways differ with regards to the size of endocytotic vesicle, the nature of the 
cargo (ligands, receptors or lipids) and the mechanism of vesicle formation. 
Dynamin is an atypically large and modular GTP-ase with domains that support PtdIns(4,5)P2 
binding, self-assembly and interaction with other endocytic components. It works as a master 
regulator of membrane internalization at the cell surface, partially as mechanochemical enzyme to 
drive membrane vesiculation (Conner and Schmid, 2003).  
Clathrin coat is a three-legged structure, called  triskelion, formed by three clathrin heavy chains. 
Each chain is tightly associated with a clathrin light chain which helps to deform the overlying 
plasma membrane into a coated pit. CME involves the concentration of high-affinity 
transmembrane receptors and their bound ligands in ‘coated pits’ on the plasma membrane. The 
coated pits are formed by the assembly of cytosolic coat proteins, the main assembly unit being 
clathrin. Coated pits invaginate and pinch off to form endocytic vesicles, that are encapsulated by a 
polygonal clathrin coat and carry concentrated receptor–ligand complexes into the cell. CME is 
crucial for intercellular communication during tissue and organ development. It furthere has an 
important role throughout the life of organism, as it modulates signal transduction by both 
controlling the levels of surface signalling receptors. It also mediates the rapid clearance and down 
regulation of activated signalling receptors. 
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The formation of coated pit requires association with the assembly proteins (AP): AP180 and 
AP2. The AP180 spontaneously binds to PtdIns(4,5)P2 and clathrin, and may help to tether clathrin 
to the membrane. Therefore, AP180 is unique to the clathrin-dependent internalization pathway. 
Transferrin is known to be specifically internalised via the clathrin-dependent pathway, and 
therefore can be employed as a marker for the clathrin–dependent endocytic compartments. 
The clathrin-mediated internalization of voltage-gated calcium channels in neurons helps to 
control the strength  and duration of synaptic transmission, and might have a role in learning and 
memory. Finally, CME is required for efficient recycling of synaptic vesicle membrane proteins 
after neurotransmission (reviewed in (Conner and Schmid, 2003)). 
Caveolae are small uncoated invaginations in the plasma membrane of strikingly regular size. 
They represent one type of cholesterol-rich domains, so called rafts, with resident caveolin 1. Their 
unique lipid composition provides a physical basis for specific sorting of membrane proteins 
(Nichols, 2003). The budding mechanism of caveolae has not been determined. It is, however, 
becoming clear that uptake by such a clathrin-independent mechanism can lead to delivery to 
caveolin-1-containing endosomes, termed caveosomes (Pelkmans and Helenius, 2002). 
Caveolar budding might be regulated by reversible phosphorylation. Caveolin 1 is phosphorylated 
on at least one tyrosin residue (Y14) in response to a variety of stimuli, such as insulin (Nichols, 
2003). Moreover, caveolin 1 interact with different signalling receptors (Liu et al., 2002). These 
data demonstrate the role of caveolin-dependent endocytosis in trafficking of signalling molecules. 
 
 1.3.2 Endocytic pathway 
Once internalized, the membrane and content of the resulting endosome can undergo different 
fates such as movement to late endosomes and lysosomes for degradation, or recycling back to the 
PM (reviewed in (Gruenberg, 2001; Nichols, 
2003; Soldati and Schliwa, 2006)).
Endocytosis is highly dynamic process. 
Definitions of endocytic compartments are 
poorly standardized. Here we used definitions 
given in (Gruenberg, 2001). The first entry 
point for internalized membrane is the so called 
early endosome, where the first step of sorting 
possibly happens. Some proteins are considered 
as organelle markers due to their restricted 
distribution, such as small GTP-ases of the Rab 
and ARF family (Fig.1-3). 
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In early endosomes, for example, Rab5 protein builds a specific effector platform, which regulates 
membrane fusion, budding and interaction with cytoskeletal components.  
Recently, it was shown that early endosoms have a highly complex organization which consist of 
cisternal regions, from which thin tubes and large vesicles emanate (Gruenberg, 2001). 
The next step in the endosome maturation are the so called endosomal carrier vesicles/ 
multivesicular bodies (ECV/MVBs), which are large endosomal structures with a limiting 
membrane and internal invaginations.  
The late endosomes have a similar multivesicular structure and represent the last state where 
sorting to recycling endosomes can occur. Otherwise proteins are targeted to final degradation 
within lysosomes. Rab7-GTPase and lysobisphosphatidic acid (LBPA) are good standardized as 
modulators and markers of late endosomes. 
Lysosomes - are cell lytic organelles. Ion pumps in their membranes provide an acidic pH within 
lumen, which is required for acidic hydrolases.  
Two different types of recycling pathway can be descriebed (Sorkin and Von Zastrow, 2002) 
(Fig. 1-3):  
1. Rapid or direct recycling is modulated through Rab4 GTPase and branches off at the 
level of early endosome with a kinetic halftime (t½) of about 2 min.  
2. Slow or indirect recycling (t½ = 10-30 min) which is processed through the 
endosomal recycling compartment (ERC) and is regulated by Rab11and ARF6 GTP-
ases. This branches off at the level of sorting and late endosomes. 
The endosomal recycling compartment (ERC) is a collection of tubular organelles with a diameter 
of about 60 nm which are associated with microtubules. Depending on cell type, the ERC tubules 
are mostly condensed around the microtubule-organizing centre or are distributed throughout the 
cytoplasm (reviewed in (Maxfield and McGraw, 2004)). 
 
 1.3.3 Cytoskeletal-based motility. 
The geometry of the cytoskeleton appears to allow two types of endosome movement in 
mammalian cells: short, non-directed movement depending on actin filaments and long, directed 
movement depending on microtubules. However, participation of the cytoskeleton architecture in 
endocytosis varies greatly among different cell types, for example in polarized cells, such as 
epithelial cells and neurons, and non-polarized cells (see below) (Murray and Wolkoff, 2003). 
 
1.3.3.1 Microtubule-dependent endocytosis  
Microtubules are dynamic protein filaments, which stretch across the cells from the “minus end” 
at the microtubule-organizing centre in the peri-centriolar area to the “plus end” at the cell 
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periphery. They provide a mechanical basis for chromosome sorting, cell polarity, organelle 
localisation and endocytic trafficking. Direct observation of endocytosis by live cell microscopy 
show that endocytic processing occurs in association with microtubules. Transport of vesicles from 
the early to late endosome state is dependent on microtubules and microtubules can promote fusion 
and fission of endocytic vesicles. Some of the so called “microtubule plus–end tracking proteins” or 
TIPs, regulate microtubule growth dynamics. They seem to be able to link endosomes to 
microtubule and participate in minus-end directed endocytosis (Wu et al., 2006). 
 
  1.3.3.2 Actin-dependent endocytosis 
Filamentous actin drives muscle contraction, cytokinesis and extension of the plasma membrane. 
It can form well-organized intracellular networks (Smythe and Ayscough, 2006). The actin 
filaments can be in general extended in two different forms: short filaments, also called cortical 
actin and long filaments, so called stress fibers. The long-distance endocytic transport along actin 
filaments can occur in some cell types, such as neurons due to short stretches of bundled, unipolar 
filaments, attached with each other along the stress fiber axis. But in general, the most important 
place for actin-dependent endocytosis is cortical, periplasmic area, where actin forms short polarity 
bundles (Murray and Wolkoff, 2003).  
Moreover, cortical actin reorganization is an important step during membrane invagination and 
internalization and can also participate in endocytic processing events of clathrin-mediated uptake. 
 
  1.3.3.3 Motor proteins 
In human the motor protein family includes about 100 members divided into 3 classes: kinesins, 
dyneins and myosins. A common functional characteristic of motor proteins in endocytosis is the 
ability to bind the vesicular cargo and transport it along cytoskeletal filaments (microtubule or 
actin) through ATP hydrolysis (is reviewed in (McGrath, 2005; Vale, 2003)).  
Kinesins bind microtubules and hydrolyze ATP to produce movement mostly toward the plus-
ends. Structural kinesins exist as an elongated dimers with an ATP-hydrolyzing motor domain on 
the N-terminus followed by a coiled-coil region, were the dimmers interact with each other. The C- 
terminal, light chain binding tail region, exirts  cargo-binding function. 
Dyneins are large microtubule motor proteins. They largely differ from kinesins and myosins. 
Dyneins are characterised by a “pinwheel with arms” structure with centrally located motor 
domains. Rotation of the motor domains causes movment of the microtubule-bound arm in a 15-nm 
“power stroke”. The cytoplasmic dynein drives a huge array of organelle transport and is often 
involved in endocytic trafficking, which originates from the cell surface and terminates at 
perinuclear lysosomes. 
 24 
The coordination of bidirectional movement is achieved by repeated binding of dyneins or 
kinesins to dynactin, a protein, linking both dyneins and kinesins to organelles and stimulating 
their movement (Dell, 2003). The capability of organelles to switch from forward to reverse 
movement and back is linked to the presence and coordination of different motors on the same 
organelle. The best-studied model system, and one that functions as a paradigm for other transport 
phenomena, is the melanosome in vertebrate cells (Soldati and Schliwa, 2006). 
Myosins structurally resemble kinesins, but have actin-based motor activity.  The large variety of 
myosins are dividet into two subclasses:  
1) the class ІІ – (muscle contraction class) which polymerize to form long structures with actin such 
as sarcomere (muscle contraction ) and contractile ring (cytokinesis); 
2) the class V – (vesicle driving class) which move cargo along actin filaments mostly towards the 
barbed-ends. Some members, like myosin VІ,  move towards pointed-ends of F-actin, analogous to 
kinesins. 
 
         1.3.4 The role of the ARF6 GTPase in endocytosis 
ARF proteins were originally identified as targets of cholera toxin - a bacterial protein catalysing 
ADP-ribosylation of G-proteins (Kahn and Gilman, 1986). They have later been shown to regulate 
membrane trafficking pathways (reviewed in (D'Souza-Schorey and Chavrier, 2006)). ARF6 
GTPase is a member of the class ІІІ ADP-ribosylation factor (ARF) family. As such it belongs to 
the RAS superfamily of small GTPases. Like Ras GTPase, ARF6 cycles between the active GTP-
bound and the inactive GDP-bound conformation, which is mediated by specific GEFs and GAPs 
respectively (see above). 
The GTP and GDP bound states determine the localization of AFR6 to different membranes. 
Thus, the GTP-bound form of ARF6 and its activated mutant ARF6_Q67L are located to the 
plasma membrane, whereas in the GDP-bound state ARF6, like its dominant negative mutant 
ARF6_T27N, localizes to the intracellular membrane compartment - the recycling endosomes 
(D'Souza-Schorey et al., 1995; Radhakrishna and Donaldson, 1997), Fig.1-4.  
Sence localization is changed during the activation-deactivation cycle of ARF6 it works like a 
shuttle between the plasma membrane and the so called tubulo-vesicular recycling endosomes. 
ARF6 exerts different effector mechanisms during membrane trafficking, the most important being 
phospholipids methabolism. ARF6 has been shown to activate phosphatidylinositol 4-phosphate 5-
kinase (PIP5K) (Honda et al., 1999; Krauss et al., 2003) as well as phospholipase D (PLD) (Brown 
et al., 1993; Cockcroft et al., 1994). At the same time, the product of PLD activity, PA, is a cofactor 
in the activation of PIP5K (Martin, 2001). Therefore, the synergistic effect of ARF6 on PIP5K and 
PLD activity can lead to a large increase of the PtdIns(4,5)P2 level at the cell periphery. 
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The best studied function of ARF6 is its participation in different levels of endocytosis (reviewed 
in (D'Souza-Schorey and Chavrier, 2006; Donaldson, 2003). 
  1.3.4.1 ARF6 facilitates membrane internalization 
In its activated state ARF6 localizes to the plasma membrane. Hydrolysis of ARF6 bound GTP 
facilitates clathrin-depependent and clathrin-independent internalisation of its ligands. This process 
is regulated by GAPs, which catalyze hydrolysis of ARF6·GTP and facilitate vesicle trafficking 
from the plasma membrane to the recycling compartment. 
It has been shown in polarized epithelial cells that ARF6 binds to the plasma membrane and 
recruits the nucleoside diphosphate kinase, NM23-H1, which provides a source of GTP for 
dynamin-dependent vesicle fission (Palacios et al., 2002). Furthermore, ARF6 is involved in 
clathrin-mediated endocytosis by direct recruitment of the adaptor protein 2 (AP2), which links the 
clathrin coat with the cargo proteins, to the plasma membrane (Paleotti et al., 2005). ARF6 
activation has also been linked to the dissociation of arrestin molecules from the G-coupled 
receptors to facilitate clathrin-mediated receptor internalisation (Claing et al., 2001; Mukherjee et 
al., 2000).  
ARF6 was shown to assotiate with the caveolae-enriched membrane fraction and the inhibition of 
its activity results in inhibition of signalling in response to vascular endothelial growth factor (Ikeda 
et al., 2005) and oncogenic RAS (Xu et al., 2003). 
ARF6 has been shown to be involved in unique clathrin- and caveolin-independent internalization 
of a number of ligands (Donaldson, 2003). 
 
   
 
 
 
 
 
1 
 
 
 
 
 
 
 
actin 
reorganisation 
actin reorganisation 
Figure 1-4. ARF6 regulates clathrin-dependent and clathrin-independent endocytic pathways 
(D'Souza-Schorey et al, 2006),  modified 
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1.3.4.2  ARF6 is required for endosome recycling 
The first evidence for ARF6 participation in endocytic recycling was demonstrated in CHO cells 
by overexpression of a dominant negative mutant, ARF6_T27N. Overexpression of ARF6_T27N 
affected the recycling of the transferrin receptor (Tfn-R) (D'Souza-Schorey et al., 1995). In HeLa 
cells the endosomal recycling compartment is very extended and can be visualized by GFP-
PLCδ(PH) which indicates  PtdIns(4,5)P2-rich compartments. ARF6 colocalizes with  PIP5K on 
these intracellular membranes (Brown et al., 2001). ARF6-labelled recycling endosomes form a 
tubular network which radiates from the pericentriolar area to the cell periphery. ARF6 can be 
colocalized with the RAB11 GTP-ase and a number of internalized molecules such as transferrin, 
β1-integrin and MHC class І, but not with early endosome marker RAB5 (Powelka et al., 2004). 
Functional assays showed that ARF6 activity affects recycling of transferrin, MHC class І, IL2 
receptor α-subunit and glycosylphosphatidylinositol (GPI)-anchored proteins (D'Souza-Schorey and 
Chavrier, 2006). ARF6 function in the trafficking of intracellular vesicles to the plasma membrane 
requires the ARF6 activation through the exchange of bound GDP with GTP. This exchange is 
facilitated by ARF6 GEF proteins. The best characterized ARF6 specific GEF is the exchange 
factor for ARF6 (EFA6), which contains Sec7 and PH domains typical for this protein family. 
Overexpression of EFA6 induces a redistribution of Tfn-Rs from the perinuclear endosomal 
compartment to the plasma membrane and the membrane ruffles (Franco et al., 1999). 
 
  1.3.4.3  ARF6 regulates actin polymerisation and membrane remodelling  
ARF6 - regulated actin remodelling is required for the formation of pseudopods and membrane 
ruffles, neurite outgrowth, cell spreading, cell migration and phagocytosis (reviewed in (D'Souza-
Schorey and Chavrier, 2006; Donaldson, 2003)). All these effects occur through the activation of 
RAC1 GTP-ase and/or lipid metabolism. 
The mechanism of ARF6-mediated RAC1 activation is not fully understood. It was shown that 
ARF6 causes redistribution of endosome-localized RAC1 to the cell surface. One of possible 
mechanism of RAC1 regulation would be the activation of some GEFs for RAC1, such as DOCK-
ELMO complex (Santy et al., 2005) or release of TIAM1 by recruitment of their downregulator, 
NM23-H 1(Palacios et al., 2002). The other RAC1 regulation way is the binding of ARF6 to POR1, 
a partner for RAC1 (D'Souza-Schorey et al., 1997). 
ARF6 can also modulate the actin cytoskeleton via activation of PIP5K and PLD which leads to 
accumulation of PtdIns(4,5)P2. It has been shown that PtdIns(4,5)P2 can stimulate actin 
polymerization through addition of actin monomers at the rapidly growing end (+) of actin 
polymers on the different way. One mechanism involves actin nucleation and filament branching by 
Arp2/Arp3 complex, activated by WASP family proteins, which besides other ligands can be 
 27 
activated by PtdIns(4,5)P2. The second mechanism is PtdIns(4,5)P2-induced dissociation of capping 
proteins from the pre-existing (+) end, such as gersolin family. The third one is PtdIns(4,5)P2-
mediated inhibition of cofilin/actin-depolimerizing factor (ADF) and as followed, a decrease of the 
number of actin nuclei.  
Actin stress fibers and cortical actin networks attach to the plasma membrane via a number of 
proteins including vinculin, talin, and ezrin/radixin/moesin (ERM) to consolidate the 
cytoskeletal/membrane linkage and to increase the adhesion to substrates. Most of these proteins are 
activated to bind actin or are directed to link actin to the transmembrane receptors by PtdIns(4,5)P2 
(reviewed in (Yin and Janmey, 2003)). 
 
  1.3.4.4  Role of ARF6 in nervous system  
Through its participation in actin cytoskeleton dynamics and membrane trafficking ARF6 plays 
important role in the most important processes in neuronal development, synaptic transmission 
effects and synaptic plasticity (reviewed in (Jaworski, 2007)). In the focus of this work it is 
important, that active ARF6 was shown to enhance neurotransmitter release (Ashery et al., 1999) 
and to facilitate AP2/clathrin recruitment to the synaptic vesicles (Krauss et al., 2003). Intriguingly, 
the tissue distribution of A-RAF and EFA6C, one of GEF isoform for ARF6, in the adult mouse 
brain is restricted to the Purkinje cells, whereas ARF6 is widely expressed in the cerebellum 
(Luckett et al., 2000; Matsuya et al., 2005). 
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1.4 Saccharomyces cerevisiae 
 1.4.1 Mitogenic cascade from yeast to man 
 Mitogen-activated protein (MAP) kinase pathway  is activated in 
response to mitogenic factors. MAP cascade posses a conserved build 
up of three serially switsched kinases. Activated MAPKKK 
phosphorylates MAPKK, which phosphorylates MAPK. 
Phosphoralates MAPK relocates into nucleus  and phosphorylates 
multiple substrates in cytosol ans nucleus.  Many of components and 
regulation mechanisms were clarified first in S. cerevisiae and are 
now known to have been conserved durig the evolution of eukariot.  
Budding yeast Saccharomyces cerevisiae is an established 
eukaryotic model organism, which played a central role in the  
  elucidation of basic cellular processes such as cell division  
  (Nurse, 1985), intracellular trafficking (Novick et al., 1980) and 
signal transduction (Madhani and Fink, 1998). In spite of the presence of two redundant RAS genes 
and at least 6 MAPK cascades (van Drogen and Peter, 2001), no RAF kinases are present in the S. 
cerevisiae genome. Yeast RAS proteins signal through the cAMP pathway (Broek et al., 1985).  One 
of the MAPK pathways in S. cerevisiae,  response to pheromone, consist STE11, STE7 and FUS3, 
which are equivalent to RAF, MEK and ERK respectively. Yeast pheromone response pathway 
governs cellular response to mating pheromone, human RAS-ERK pathway respond to extracellular 
mitogens (Fig.1-8).                                                                                                                                                                                                                                                                                                               
RAF isoforms are highly promiscuous in their interactions and are known to form heterodimers in 
mammalian cells. Heterodimerization was shown to be a prerequisite for transactivation of RAF 
isoforms(Rapp et al., 2006). On this background, a system allowing the investigation of a single 
RAF isoform function is highly desirable.  
 
 1.4.2  Regulation of actin polymerization and endocytosis in yeast 
In yeast, the actin cytoskeleton comprises two types of structure: actin patches, containing F-actin, 
that localize to the cell cortex, and actin cables, which are distributed throughout the cytoplasm. 
Regulation of cortical actin patches assembly and their rearrangement in response to internal and 
external signals is regulated through actin-binding proteins, many of which have functional 
homologues in higher eukaryotic cells. Actin polymerization is essential for cell polarization, 
cytokinesis and endocytosis. Many of the endocytic proteins, such as AP-2, Hip1/Sla2p, epsin/ 
Ent1p/Ent2p, have binding sites for PtdIns(4,5)P2. However, the standart marker of PtdIns(4,5)P2, 
Figure 1-8. MAPK 
cascades are conserved 
during evolution. 
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PLCδ-PH domain, when expressed as GFP fusion in yeast, labelled  the yeast plasma membrane 
uniformly instead of showing a patch-like localization that would be characteristic of endocytic 
proteins. Recent studies identified a new PtdIns(4,5)P2 binding domain, the AP180 N-terminal 
homology (ANTH) domain, which could detect PtdIns(4,5)P2 on endocytic sites (Sun et al., 2007). 
In yeast PtdIns(4,5)P2 plays a key role in actin assembly and endocytosis (Stefan et al., 2005; Sun et 
al., 2005). Moreover, the yeast homolog of mammalian ARF6, Arf3p was shown in an earlier studies 
to regulate cortical actin formation but not endosytosis of a fluid-phase marker (Huang et al., 2003). 
Recent data indicates, that Arf3p localizes at sites of endocytosis and is necessary for wild-type levels 
of PtdIns(4,5)P2  at the plasma membrane (Smaczynska-de Rooij et al., 2008). 
In conclusion, involvement of PtdIns(4,5)P2 in actin recruitment and vesicle formation are likely to 
be conserved across eukaryotic evolution. 
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2. Materials 
2.1 Escherichia coli strains 
Strain Genotype  Source 
DH5αF' F-superE44 ∆lacU169 (φ80 
lacZ∆M15) hsdR17(rK-
,mK+) recA1 endA1 gyrA96 
thi-1 relA 
Bethesda Res. Lab. (BRL) 
BL21 (DE3) F- ompT gal [dcm] [lon] 
hsdSB  (rb- mb- ; an E. coliB 
strain) with DE3, a λ 
prophage carrying T7 RNA 
polymerase gene
 
Novagen 
 
2.2  Yeast strains 
Strain Genotype Source 
BJ5459 MATa ura3 leu2 his3 lys2 
pep4::HIS3 prb1D1.6R kan1 
Yeast Genetic Stock Center, 
UC Berkeley, USA
 
cl3-ABYS-86 MAT  ura3-5 leu2-3 112 his3 
pra1-1 prb1-1 prc1-1 cps1-3 
can
R
 
   D. H. Wolf (University of 
    Stuttgart, Germany) 
 
cl3-ABYS-86 ∆bmh2 MAT  ura3-5 leu2-3 112 his3 
pra1-1 prb1-1 prc1-1 cps1-3 
can
R  bmh2::kan1  
  Stefan Albert, University of        
, Würzburg, Germany 
 
2.3 Escherichia coli plasmids 
Vector Description Source 
pGEX-TT for expression of GST fusion 
proteins in E. coli 
contains the polylinker from 
pEG-KT 
Stefan Albert, University of 
Würzburg, Germany 
pGEX-TT-AR149 for production of GST- E. Nekhoroshkova 
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AR149 in E. coli 
pGST-GGA3 for production of GST-GGA3 
in E. coli 
Margaret Chou, University of 
Pennsylvania, USA 
 
2.4 Saccharomyces cerevisiae plasmids 
pEG-KT 2µ; URA3; GAL UAS-CYC3 
driven production of GST 
fusion proteins in yeast 
Mitchell et al., (1993) 
pEG-KT-A-RAF for production of GST-A-
RAF in S. cerevisiae 
E. Nekhoroshkova 
pEG-KT-B-RAF for production of GST-B-RAF 
in S. cerevisiae 
Stefan Albert, University of 
Würzburg, Germany 
pEG-KT-C-RAF for production of GST-C-RAF 
in S. cerevisiae 
Stefan Albert, University of 
Würzburg, Germany 
pYES-2 2µ; URA3, GAL1 promotor Invitrogen 
pYES-2-B-RAF for production of His-tagged  
B-RAF in S. cerevisiae 
E. Nekhoroshkova 
pYES-2-B-RAF_S364A for production of His - tagged  
B-RAF 14-3-3 binding mutant 
in S. cerevisiae 
E. Nekhoroshkova 
pYES-2-B-RAF_S728A for production of His - tagged  
B-RAF 14-3-3 binding mutant 
in S. cerevisiae 
Stefan Albert, University of 
Würzburg, Germany 
pYES-2-B-RAF_S364A,        
S728A 
for production of His - tagged  
B-RAF 14-3-3 binding double 
mutant in S. cerevisiae 
Stefan Albert, University of 
Würzburg, Germany 
pUG36 2µ; URA3,  
MET25-P promoter 
for expression of GFP-tagged 
proteins in S. cerevisiae 
J.H. Hegemann at al., (1996) 
pUG36-B-RAF for expression of GFP-tagged 
B-RAF in S. cerevisiae 
E. Nekhoroshkova 
pUG36-C-RAF for expression of GFP-tagged 
C-RAF in S. cerevisiae 
E. Nekhoroshkova 
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pUG36-C-RAF-C4 for expression of GFP-tagged 
C-RAF deletion mutant  
in S. cerevisiae 
E. Nekhoroshkova 
pUG36-A-RAF for expression of GFP-tagged 
A-RAF in S. cerevisiae 
E. Nekhoroshkova 
pUG36-AR149 for expression of GFP-tagged 
A-RAF deletion mutant  
in S. cerevisiae 
E. Nekhoroshkova 
pUG36-A-RAF_1-230 for expression of GFP-tagged 
A-RAF deletion mutant  
in S. cerevisiae 
E. Nekhoroshkova 
pUG36-A-RAF_1-312 for expression of GFP-tagged 
A-RAF deletion mutant  
in S. cerevisiae 
E. Nekhoroshkova 
pUG36-A-RAF_1-388 for expression of GFP-tagged 
A-RAF deletion mutant  
in S. cerevisiae 
E. Nekhoroshkova 
pUG36-A-RAF_88-606 for expression of GFP-tagged 
A-RAF deletion mutant  
in S. cerevisiae 
E. Nekhoroshkova 
pUG36-A-RAF_142-606 for expression of GFP-tagged 
A-RAF deletion mutant  
in S. cerevisiae 
E. Nekhoroshkova 
pUG36-A-RAF_205-606 for expression of GFP-tagged 
A-RAF deletion mutant  
in S. cerevisiae 
E. Nekhoroshkova 
pUG36-A-RAF_306-606 for expression of GFP-tagged 
A-RAF deletion mutant  
in S. cerevisiae 
E. Nekhoroshkova 
pUG36-A-RAF_1-96 for expression of GFP-tagged 
A-RAF deletion mutant  
in S. cerevisiae 
E. Nekhoroshkova 
pUG36-A-RAF_18-96 for expression of GFP-tagged 
A-RAF deletion mutant  
E. Nekhoroshkova 
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in S. cerevisiae 
pUG36-AR149_R52L for expression of GFP-tagged 
A-RAF deletion mutant with 
Ras-binding site mutation  
in S. cerevisiae 
E. Nekhoroshkova 
pUG36-A-RAF_R52L for expression of GFP-tagged 
A-RAF Ras-binding site 
mutant in S. cerevisiae 
E. Nekhoroshkova 
pUG36-A-RAF_ 
R103A,K104A 
for expression of GFP-tagged 
A-RAF phosphatidylserine 
binding site mutant  
in S. cerevisiae 
E. Nekhoroshkova 
pUG36-A-RAF_ 
R359A,K360A 
for expression of GFP-tagged 
A-RAF phosphatidic acid -
binding site mutant in S. 
cerevisiae 
E. Nekhoroshkova 
 
2.5 Mammalian expression vectors 
pcDNA3 CMV-promotor,  
for expression of proteins in 
mammalian cells 
Invitrogen 
pcDNA3-Myc-A-RAF for expression of Myc-tagged 
A-RAF in mammalian cells 
Angela Baljuls, University of 
Würzburg, Germany 
pcDNA3-Myc-A-RAF_DD for expression of Myc-tagged 
A-RAF dominant active 
mutant in mammalian cells 
Angela Baljuls, University of 
Würzburg, Germany 
pEGFP-N1-ARF6 for expression of GFP-tagged 
ARF6 protein in mammalian 
cells 
Antoine Galmiche, University 
of Würzburg, Germany 
pEGFP-N1-ARF6_Q67L for expression of GFP-tagged 
ARF6 dominant active mutant 
in mammalian cells 
E. Nekhoroshkova 
pEGFP-N1-ARF6_T27N for expression of GFP-tagged 
ARF6 dominant negative  
E. Nekhoroshkova 
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mutant in mammalian cells 
pLNCX-HA-ARF6 for expression of HA-tagged 
ARF6 protein in mammalian 
cells 
Margaret Chou, University of 
Pennsylvania, USA 
pLNCX-HA-ARF6_Q67L for expression of HA-tagged 
ARF6 dominant active mutant 
in mammalian cells 
Margaret Chou, University of 
Pennsylvania, USA 
pLNCX-HA-ARF6_T27N for expression of HA-tagged 
ARF6 dominant negative  
mutant in mammalian cells 
Margaret Chou, University of 
Pennsylvania, USA 
pFLAG-EFA6 for expression of FLAG-
tagged EFA6 protein in 
mammalian cells 
Margaret Chou, University of 
Pennsylvania, USA 
pEGFP-C1 CMV-promotor,  
for expression of GFP-tagged 
proteins in mammalian cells 
Invitrogen 
pEGFP-C1-C-RAF for expression of GFP-tagged 
C-RAF in mammalian cells 
Andreas Fischer, University 
of Würzburg, Germany 
pEGFP-C1-C-RAF-C4 for expression of GFP-tagged 
C-RAF deletion mutant in 
mammalian cells 
 
E. Nekhoroshkova 
pEGFP-C1-A-RAF for expression of GFP-tagged 
A-RAF in mammalian cells 
Angela Baljuls, University of 
Würzburg, Germany 
pEGFP-C1-AR149 for expression of GFP-tagged 
A-RAF deletion mutant in 
mammalian cells 
E. Nekhoroshkova 
pEGFP-C1-A-RAF_205-606 for expression of GFP-tagged 
A-RAF deletion mutant in 
mammalian cells 
E. Nekhoroshkova 
pEGFP-C1-A-RAF_R52L for expression of GFP-tagged 
A-RAF Ras-binding site 
mutant in mammalian cells 
E. Nekhoroshkova 
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2.6 Oligonucleotides 
Oligonucleotides used in this work were custom-synthesized by Metabion (Martinsrid, Germany) 
  2.6.1 Oligonucleotides for PCR amplification of A-RAF gene  
  and its truncations. 
A-RAF_for  5’- CGC ACT AGT ATG GAG CCA CCA CGG GG-3’ 
AR149_for 5’- CGA GGA TCC ATG GAG CCA CCA CGG-3’ 
AR149_rev 5’- CGA AGC TTC TAG GTA GTG ATG TCA ACA CAG-3’ 
AR149 (6*His) rev 5’ – CGA AGC TTC TAA TGA TGA TGA TGA TGA TGG GTA CTC 
ATG TCA ACA CAG-3’ 
A-RAF 1-230_for 5’- CGA AGC TTC TAG TTG GAG TCC ATG GGG G-3’ 
A-RAF 1-312_rev 5’- GCG AAG CTT CTA CAG CTG CAC CTC ACT G-3’ 
A-RAF 1-388_rev 5’- CG AAG CTT CTA GCC CTC ACA CCA CTG TG-3’ 
A-RAF 88-606_for 5’-GCG ACT AGT ATG GTC GAG GTC CTT GAA GAT-3’ 
A-RAF 142-606_for 5’- GCG ACT AGT ATG ACA GTC TGT GTT GAC ATG AG-3’ 
A-RAF 205-606_for 5’- CTC CCG GGA TGG CCC CCC TAC AGC GCA TC-3’ 
A-RAF 306-606_for 5’- CTC CCG GGA TGC CAC CCA GTG AGG TGC AG-3’ 
A-RAF 606_rev 5’- CGA AGC TTC TAA GGC ACA AGG CGG G-3’ 
A-RAF-RBD_for 5’- CGC AAG CTT CAT ATG GTG GGC ACC GTC AAA G-3’ 
A-RAF_RBD_rev 5’- GCG CTC GAG CTA CAG CGG GAC ATC TTC-3’ 
 
  2.6.2 Oligonucleotides for mutagenesis 
A-RAF_ R52L_for 5’- GAC AAG GCC CTG AAG GTG CTG GGT CTA AAT CAG GAC 
TGC-3’ 
A-RAF_R52L_rev 5’- GCA GTC CTG ATT TAG ACC CAG CAC CTT CAG GGC CTT 
GTC – 3’ 
A-RAF_R103A, 
K104A_for 
5’- C ATG CAC AAT TTT GTA GCG GCG ACC TTC TTC AGC 
CTG-3’ 
ARAF_R103A, 
K104A_rev 
5’- CAG GCT GAA GAA GGT CGC CGC TAC AAA ATT GTG CAT 
G-3’ 
ARAF_R359A, 
K360A_for 
5’- GAG ATG CAG GTG CTC GCG GCG ACG CGA CAT GTC AAC-
3’ 
ARAF_R359A, 
K360A_rev 
5’- GTT GAC ATG TCG CGT CGC CGC GAG CAC CTG CAT CTC-
3’ 
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ARF6(Q67L)_for 5’- GGA TGT GGG CGG CCT AGA CAA GAT CCG GCC-3’ 
ARF6(Q67L)_rev 5’- GGC CGG ATC TTG TCT AGG CCG CCC ACA TCC-3’ 
ARF6(T27N)_for 5’- GGA CGC GGC CGG CAA GAA CAC AAT CCT GTA CAA G -3’ 
ARF6(T27N)_rev 5’- CTT GTA CAG GAT TGT GTT CTT GCC GGC CGC GTC C-3’ 
 
2.7 Antibodies 
2.7.1 Primary antibodies 
Name Application Sourse 
rabbit anti-Emp47p Western Blot, 1:1000 D.Gallwitz Lab, MPI,  
Göttingen 
rabbit anti-Kar2p Western Blot, 1:3000 D.Gallwitz Lab, MPI,  
Göttingen 
rabbit anti-CPYp Western Blot, 1:5000 D.Gallwitz Lab, MPI,  
Göttingen 
rabbit anti-Kar2p Western Blot, 1:5000 D.Gallwitz Lab, MPI,  
Göttingen 
rabbit anti-Rer1p Western Blot, 1:1000 D.Gallwitz Lab, MPI,  
Göttingen 
mouse anti-GFP (B2) Western blot 1:1000 
Immunoprecipitation 1:100 
Santa Cruz Biotechnology, 
USA 
rabbit  anti-14-3-3 β (K19) Western blot 1:1000 
 
Santa Cruz Biotechnology, 
USA 
rabbit anti-A-RAF (C20) Western blot 1:1000 
Immunocytochemie 1:50  
Santa Cruz Biotechnology, 
USA 
rabbit anti-B-RAF (C19) Western blot 1:1000 
 
Santa Cruz Biotechnology, 
USA 
rabbit anti-C-RAF (C12) Western blot 1:1000 
 
Santa Cruz Biotechnology, 
USA 
mouse anti-β-tubulin  
MAB3408 
Immunocytochemie 1:50 Chemicon International, USA 
mouse anti-c-Myc (9E10) Western blot 1:1000 
Immunoprecipitation 1:100 
Santa Cruz Biotechnology, 
USA 
 37 
mouse anti-C-RAF  
pS621 (6B4) 
Western blot 1:1000 nanoTools, Germany 
mouse anti-C-RAF pS259 Western blot 1:1000 Cell Signalling, USA 
mouse anti-ERK2 (C14)  Western blot 1:1000 Santa Cruz Biotechnology, 
USA 
mouse anti-pERK - p44/42 
MAPK (Tyr202/Tyr204) E10  
Western blot 1:1000 Cell Signalling, USA 
mouse anti-HA (HA.C5) Western blot 1:1000 
Immunoprecipitation 1:100 
Santa Cruz Biotechnology, 
USA 
mouse anti-His Tag (4D11) Western blot 1:1000 Upstate, USA 
rabbit anti-GST (A5800) Western blot 1:100000 Invitrogen, USA 
 
  2.7.2 Secondary antibodies   
ECL™ anti-mouse 
Horseradish Peroxidase linked  
whole antibody; from sheep; 
NA931V 
Western blot 1:5000 Amersham, UK 
ECL™ anti-mouse 
Horseradish Peroxidase linked  
whole antibody; from donkey; 
NA934V 
Western blot 1:5000 Amersham, UK 
anti-mouse FITC-conjugated 
donkey antibody 
Immunocytochemie 1:100 Jackson ImmunoResearch 
Laboratories, UK 
anti-rabbit FITC-conjugated 
donkey antibody 
Immunocytochemie 1:100 Jackson ImmunoResearch 
Laboratories, UK 
anti-mouse CY5-conjugated 
donkey antibody 
Immunocytochemie 1:100 Jackson ImmunoResearch 
Laboratories, UK 
anti-rabbit CY5-conjugated 
donkey antibody 
Immunocytochemie 1:100 Jackson ImmunoResearch 
Laboratories, UK 
anti-rabbit TRITC Immunocytochemie 1:100 Jackson ImmunoResearch 
Laboratories, UK 
anti-mouse TRITC Immunocytochemie 1:100 Jackson ImmunoResearch 
Laboratories, UK 
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2.8 Chemical reagents and general materials 
 
Reagent         Purchased from 
1 kb DNA ladder        Fermentas 
Acrylamide (30%)/Bisacrylamide (0,8%)     Roth 
Adenosin-5’Triphosphate (ATP)      Sigma 
Agarose        Roth 
Ammonium Acetate        Sigma 
Ammonium peroxydisulfate (APS)      Sigma 
Ampicillin         Sigma 
AntifoamA         Sigma 
Aprotinin         Roth 
Bacto-Agar         DIFCO 
Bovine serum albumin (BSA)      Sigma 
Bradford-reagent        Sigma 
Bromphenolblue        Sigma 
β-Mercaptoethanol        MERK 
Calciumchloride (CaCl2)       Sigma 
Chloroform         Roth 
Dimethylsulfoxide (DMSO)       Sigma 
Dithiothreitol (DTT)        Sigma 
dNTP          Fermentas 
Ethylenediaminetetraacetic acid-disodium salt (EDTA)  Sigma 
EGTA         Sigma 
Ethanol         AppliChem 
Ethidiumbromide        Sigma 
Glutathion-sepharose       Amersham    
Glycerol         Roth 
Hydrochloride (HCl)       Roth 
IGEPAL (NP-40)        Fluka 
Isoropyl-1-thio-ß-D-thiogalactopyranoside (IPTG)    Roth 
Isopropanol         Applichem 
Leupeptin         Sigma 
L-Arginine         Sigma 
L-Lysine         Sigma 
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L-Methionine         Sigma 
L-Phenylalanine        Sigma 
L-Threonine         Sigma 
L-Tryptophan        Sigma 
Magnesiumchloride        Sigma 
Phenol         Roth 
Phenol/Chloroform (TE saturated)      Sigma 
PIPES         Sigma 
PMSF         Fluka 
Ponceau S         Sigma 
Potassium acetate (KAc)       Roth 
Potassiumchloride (KCl)       Roth 
Potassiumdihydrophosphate (KH2PO4)     Merck 
Protein A-agarose        Roche 
Protein G-agarose        Roche 
Protein ladder        Fermentas 
SDS ultra pure        Roth 
Sodium citrate        Merck 
Sodiumdihydrophosphate (NaH2PO4)     AppliChem 
Sodiumhydrophosphate (NaHPO4)      AppliChem 
Sodiumhydroxide (NaOH)       Sigma 
Sodium orthovanadate       Sigma 
TEMED         Sigma 
Tris-(hydroxymethyl)-aminomethane (Tris)    Roth 
Triton-X100         Sigma 
Tyrosine         Sigma 
Uracil          Sigma 
Whatman 3MM Paper       Schleicher & Schüll 
X-ray film         Hartenstein 
Yeast extract        DIFCO 
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2.9 Enzymes 
Items          Source 
Calf Intestinal Phosphatase (CIAP)     Fermentas 
Bio Therm DNA polymerase      Gene Craft 
DNA-Polymerase I, (Klenow-Fragment)    Fermentas 
Deep Vent DNA polymerase      NEB 
Pfu DNA polymerase       Stratagene 
Pfu Turbo DNA Polymerase      Stratagene 
RNaseA         Roche 
T4 Ligase         Fermentas 
Resriction Endonucleases      Fermentas, NEB 
 
2.10 Kits 
Items          Source 
ECL Western blotting detection reagents    Amersham 
QIAEX II Gel Extraction Kit      Qiagen 
QIAGEN Plasmid Kit (Mini, Midi)      Qiagen 
QIAquick PCR purification Kit        Qiagen 
  mi - plasmid miniprep Kit      Metabion 
 mi – gel extraction Kit      Metabion 
 
2.11 Cell culture 
  2.11.1 Cell lines 
HeLa   - epithelial-like cell line from human cervix carcinoma 
   ATCC [America Type Culture Collection] CCL-2 
COS 7   - simian cell line from african green monkey kidney, 
   fibroblast-like cells growing as monolayers. 
   ATCC CRL-1651 
NIH3T3  - fibroblast cell line from mouse Swiss NIH embryo,  
   immortalise, contact inhibited, DMEM 10% FCS 
   ATCC  CRL-1711  
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  2.11.2 Cell culture materials 
Items         Source  
DMEM         Invitrogen 
EGF         Cell Systems 
FCS         PanBiotech 
HBSS         Invitrogen 
L-Glutamine        Invitrogen 
Penicillin-Streptomycin      Invitrogen 
Trypsin-EDTA        PanBioteh 
 
2.12 Instruments 
 
Hardware       Manufacturer 
Bacterial incubator      Heraeus B 6200 
Cell culture incubator     Heraeus Instrument 
Cell culture microscope     Leica 
Cell culture hood     Gelaire Flow Laboratories  
Cover glasses      Hartenstein 
Developing machine     CP100, Agfa 
Electrophoresis power supply    Bio-Rad 
Electrophoresis unit, small     Bio-Rad Mini-Protean II 
Fluorescence microscope     DMIRBE, Leica  
Freezer (-20ºC)     Liebherr 
Freezer (-80ºC)     ULT, Thermo Scientific 
Heat block       Liebisch, Type 2099-DA 
Horizontal electrophoresis gel   MWG Biotech 
Magnetic stirrer     IKA Labortechnik 
Mega centrifuge      J-6B, Beckman; 
       J2-HS, Beckman;  
       Megafuge 1.0 R, Heraeus; 
       RC 5B plus, Sorval 
Microscope Slides, Super Frost® Plus  Menzel-Gläzer 
Mini centrifuge      5417R, Eppendorf 
pH meter       inolab720, WTW 
PCR machine      primus 96 advance, peqlab 
Power supplier     BioRad 
Refrigerated incubator shaker    innova 4330, New Brunswick Scientific 
Refrigerator       Premium, Liebherr 
Spectrophotometer      Ultraspec 3000, Pharmacia Biotech 
Thermomixer comfort    Eppendorf 
Ultracentrifuge     Optima L-80 XP, Beckman Coulter   
Ultraviolet Crosslinker    UVC500 Hoefer Scientific Instruments 
Vortex       Scientific Industries Genie-2 
Water bath       GFL 1083, Amersham-Buchler 
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3. Methods 
3.1  Microbiological Methods  
 3.1.1  Cultivation of Escherichia coli 
  3.1.1.1  Growth media for Escherichia coli  
LB-Medium: 5 g/l yeast extract 
  10 g/l trypton 
  5 g/l NaCl 
  5 ml/l 1 N NaOH 
 
Additives:        final concentration:  
 
Antibiotics: Ampicillin:    50 µg/ml     
 Chloramphenicol   30 µg/ml    
 Kanamycin  50 µg/ml 
 Tetracycline  15 µg/ml 
 
IPTG      0.1-1 mM 
 
2xYT-Medium:  10g/l yeast extract 
  16 g/l trypton 
  5 g/l NaCl 
  5 ml/l 1 N NaOH 
 
For plates, 2% (w/v) agar has been added prior to sterilization. Sterilization was performed in an 
autoclave under the following conditions: 20 min at 121°C. Antibiotics were added after 
sterilization, to media chilled to approximately  50°C.  
All media were stored at 4°C until use.  
 
3.1.1.2     Growth and storage of Escherichia coli cultures 
Escherichia coli strains and transformants were inoculated from a fresh agar plate into liquid 
medium, containing antibiotics when necessary. Luquid cultures were incubated with shaking (180 
rpm) at 37°C. Permanent cutures were prepared by mixing 500 µl of logarithmically-growing 
bacteria with 500 µl of sterile glycerol. Thus prepared, cells were shock-frozen in liquid nitrogen 
and stored at -70°C.  
 43 
3.1.2 Cultivation of Saccharomyces cerevisiae 
 3.1.2.1 Growth media for Saccharomyces cerevisiae 
 YEPG-Medium: 10.0 g/l yeast extract 
   20.0 g/l pepton (Nr. 190) 
   20.0 g/l glucose 
 
YEPGal-Medium: 10.0 g/l yeast extract 
  20.0 g/l pepton (Nr. 190) 
  20.0 g/l galactose 
 
PM-Medium: 6.7 g/l yeast nitrogen base w/o AA 
  5.0 g/l pepton (Nr. 140) 
  20.0.g/l glucose or galactose 
 
SD-Medium (Minimal medium): 6.7 g/l yeast nitrogen base w/o AA 
  20.0 g/l glucose 
SGal-Medium (Minimal medium):6.7 g/l   yeast nitrogen base w/o AA 
  20.0 g/l galactose 
Additives for minimal media:  
 Amino acids: 20 mg/l L-histidine 
  60 mg/l L-leucine 
  30 mg/l L-lysine (mono-HCl) 
  40 mg/l L-tryptophan 
 
 Bases: 40 mg/l adenine 
  20 mg/l uracil 
 
 Antibiotics:               200 mg/l    Geneticin 418  
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For plates, 2% (w/v) agar has been added prior to sterilization. Sterilization was performed in an 
autoclave for 20 min at 121°C. Antibiotics were added after sterilization, after media were chilled to 
approximately 50°C.  
All media were stored at 4°C until use.  
 3.1.2.2  Growth and storage of Saccharomyces cerevisiae cultures  
Plates:  
S.cerevisiae was inoculated on corresponding plates from the permanent culture and incubated at 
25-30°C. Such plates could be stored for several weeks at 4°C.  
 
Liquid cultures:  
50-100 ml of medium containing all requirements for growth and selection of the culture was 
inoculated from the plate and shaken at 25°C or 30°C untill  the optical density at 600 nm (OD600) 
reached the required value.  
For cultivation of greater amounts of S.cerevisiae, 100 ml of liquid culture was used for inoculation 
of 1 liter of medium.  
 
Permanent cultures:  
0.5 ml of overnight liquid culture was mixed with equal volume of 50% sterile glycerol and stored 
frozen at -70°C. These stocks can be used for several years, when stored at the temperature of -
70°C. 
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3.2 Molecular Biological Methods 
3.2.1  Isolation of plasmid DNA 
3.2.1.1.  Analytical and large scale DNA preparation. 
For analytical  DNA preparation 5 ml E.coli overnight culture + antibiotic were sedimented  and 
followed to DNA preparation according protocol for miniprep kits from QUIAGEN  or Metabion.   
Greater amounts (100-500 µg) for ultra pure plasmid DNA were prepared by using QIAGEN ion 
exchange columns (midi and maxi). Culture volumes for these preparations were 100-500 ml of LB 
+ antibiotic. Buffers and protocols delivered by manufacturer were employed.  
 
3.2.1.2  Genomic DNA preparation from Saccharomyces cerevisiae 
 
DNA was isolated according to Hoffman and Winston (1987) . 2 -4 ml of overnight S.cerevisiae 
culture were centrifuged at 10 000 rpm for 5 minutes. Cell pellets were washed once with STES 
buffer and resuspended in 40 µl of this buffer. Acid-washed glass beads were added to 80% volume 
and the test tubes were vortexed for 5 min. 200 µl of TE buffer and 200 µl of phenol were added to 
the mixture, followed by vortexing for 2 min. After vortexing, test tubes were centrifuged for 5 min 
at 14 000 rpm. Aqueous phase (upper) was extracted twice with chloroform, then was precipitated 
with 0.7 volumes of isopropanol, rinsed twice with 70% ethanol and dissolved in 100 µl of TE 
buffer. genomic DNA was used directly as a template for polymerase chain reaction  
 
STES buffer: 
 
1% (v/v) sodium dodecyl sulfate (SDS) 
100 mM NaCl 
10 mM Tris.Cl, pH 8.0 
1 mM EDTA, pH 8.0 
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3.2.2  Spectrophotometric determination of the concentration and the purity of 
DNA solutions 
 
The concentration and the purity of nucleic acids were determined by measuring the absorbance 
of properly diluted solutions at wave lengths λ=260 nm, and λ=280 nm against the used buffer. 
Absorbance A260=1 measured under standard conditions (1ml volume and 1 cm cuvette) means the 
following concentrations:  
 50 µg/ml of double-stranded DNA 
 40 µg/ml of RNA or single-stranded DNA 
 20 µg/ml of oligonucleotides 
 
Aromatic residues such as amino acids tyrosine, tryptophan, phenylalanine but also phenol absorb 
at λ=280 nm stronger than DNA. From that, protein and phenol contamination can be estimated by 
ratio between A260 and A280 values. A260 : A280 values < 1.8 (or < 2.0 for RNA) indicate protein 
or phenol contamination.  
 
3.2.3 Enzymatic treatment of DNA 
 3.2.3.1 Digestion of double-stranded DNA with restriction  endonucleases 
Today, about 200 restriction endonucleases are available from different manufacturers. They 
mostly belong to type II restriction endonucleases that recognize palindromic sequences (with a 
twofold symmetry axis). The recognition sequences may be four to eight base pairs long and are 
being cut within or immediately next to the recognition sequence. Dependent on the used enzymes 
and their cutting sites, sticky (5'-protruding or 3'-protruding single strand DNA) or blunt-ended 
DNA fragments can be generated.  
The used enzyme was added (~1 unit per µg DNA) to the solution containing  the DNA to be 
restricted,  the corresponding buffer (delivered by the manufacturer in 10x concentration). Reaction 
volumes were 15 or 50 µl for analytic and preparative digestions respectively. Reaction mixtures 
were incubated at recommended temperatures for 1-3 hours.  
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3.2.3.2 Dephosphorylation of linearized DNA fragments  
Removal of 5'-phosphate residues is catalyzed by alkaline phosphatase (Calf Intestinal, CIAP 
from Boehringer Mannheim). Thus treated vectors loose the possibility to self-ligate, which 
decreases the background during cloning of DNA fragments.  
For dephosphorylation, about 5 µg of linearized DNA was dissolved in 50 µl of 1x CIAP buffer 
and incubated with 1 unit of alkaline phosphatase for 30 min at 37°C. The enzyme was inactivated 
by phenol/chloroform extraction or separated away by preparative gel electrophoresis. During 
dephosphorylation, some bases can be removed from the DNA strand, therefore it is suitable to 
decrease the enzyme amount or to use shorter incubation times.  
 
CIP buffer (10x concentrated):  
500 mM Tris-HCl, pH 8.5 
1 mM EDTA 
 
3.2.3.3  "Repairing" of 3'-or 5'-overhangs to generate blunt ends 
"Blunting" of cohesive DNA ends was used when incompatible DNA ends were to be ligated.  
For this purpose, the Klenow fragment of E. coli DNA polymerase I (Klenow and Henningsen, 
1970) was used, which fills in 5'-overhangs by its polymerase activity, whereas 3'-overhangs are 
removed by residual 3'to5'- exonuclease activity. This polymerase is active in any restriction buffer, 
therefore no buffer change after restriction nuclease digestion was necessary.  
To 4-5 µg of DNA digested with restriction endonucleases in 50 µl volume, 1 µl of 
deoxyribonucleotide stock solution was added. After the addition of 1 to 5 U of the Klenow 
fragment, the mixture was incubated at 30°C for 15 min. The reaction was stopped by heating to 
75°C for 10 minutes. For generation of sticky-blunt ends by selective repair of ends generated by 
one enzyme, reaction was first cleaved by the first enzyme, and rendered blunt-ended by the 
Klenow enzyme. The enzyme was inactivated by heating to 75°C for 10 minutes, and the DNA 
subsequently cleaved by the second enzyme.  
Deoxyribonucleotides stock solution (in water): 
  2.5. mM dATP 
  2.5. mM dGTP 
  2.5. mM dCTP 
  2.5. mM dTTP 
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3.2.3.4  Ligation of DNA fragments 
Linearized DNA fragments can be connected by formation of phosphodiester bonds between 
adjacent 5'phosphate and 3' OH residues. T4 DNA ligase catalyses this reaction powered by 
hydrolysis of one ATP molecule.  
The reaction contained about 100 ng of linearized vector DNA and a five to ten fold molar excess 
of the DNA fragment to be inserted, in the volume of 15µl of 1x ligation buffer (commercial, 
Fermentas). 1 unit of T4 DNA ligase was added and the reaction was incubated for 1 hour to 
overnight at RT (blunt ends) or 15°C.  
3.2.4  Agarose gel electrophoretic separation of DNA fragments 
 
The agarose gel electrophoresis is a method  for separation of large (0.5-25 kbps) DNA fragments. 
Due to the negative charge of phosphate groups present in the structure, DNA moves towards the 
positively charged anode in an electric field. The electrophoretic mobility of DNA fragment is 
proportional to the logarithm of its molecular mass (Helling et al., 1974). The length and the 
amount of DNA fragments was estimated by comparison of the mobility and fluorescence of the 
fragment with the molecular mass standard. Molecular mass standards used in this work were from 
Fermentas. Concentration of agarose was varied from 0.7% to 2%, dependend on the size of the 
separated DNA fragments.  
Agarose gels were prepared by resuspending the required amount of agarose in 1x TAE buffer 
and boiling in the microwave oven for 3-4 minutes. After a short cooling, the agarose solution was 
poured into the mold with the comb. After the gel hardened completely, the comb was pulled out, 
the gel was mounted in the electrophoresis chamber and overlayed with 1xTAE buffer. Samples to 
be separated were prepared in the loading buffer and loaded into the slots prepared by the comb.  
The electrophoresis was carried out at 5V/cm and controlled by the mobillity of the 
electrophoretic marker dyes. After the electrophoresis the gel was stained with ethidium bromide, 
which allows the visualization of DNA fragments by fluorescence after illumination with UV 
transluminator (λ = 302 or 366 nm). Depending upon requirements, the stained gel was either 
photographed or used for isolation of DNA fragments.  
10x gel loading buffer:  
20% Ficoll 400 
0.1 M EDTA, pH 8 
1.0% sodium dodecyl sulfate 
0.25% Bromphenol blue 
0.25% xylene cyanol 
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TAE electrophoretic buffer (50x stock solution): 
242 g Tris base 
57.1 ml glacial acetic acid 
37.2 g EDTA disodium salt 
H2O to 1 liter 
 
Ethidium bromide solution: 
1 µg/ml ethidium bromide in water 
 
3.2.5   Isolation of DNA fragments from agarose gels 
DNA fragments were isolated from the gel pieces containing DNA fragment by QIAquick Gel 
Extraction Kit from QIAGEN according protocol from  manufacturer. 
 
3.2.6 Preparation of competent Escherichia coli 
E.coli cells were platted on LB Petri plate without antibiotics and incubate on 37ºC overnight.  
250 ml of SOB-medium were inoculated with 10-12 big colonies picked from the plate. The culture 
was incubated with shaking at 180 rpm to an OD600 = 0.4-0.6. Cells were chilled on ice for 10 
minutes and then harvested in sterile 500 ml centrifugation bottle. The bottle was centrifuged at 
4000 rpm for 10 minutes in a precooled rotor.  
Cell pellet was washed in 80 ml ice-cold TB-buffer, chilled on ice for 10 min and harvested.  
Pellet was resuspended in 20 ml ice-cold TB buffer with adding from 1.4 ml DMSO (7% end 
concentration). Cells suspension was incubated on ice for 10 min, 200 µl aliquots were frozen in 
liquid nitrogen and stored at -80°C. 
  
   SOB-medium 
 2%          Bacto Trypton 
 0.5%       yeast extract 
 10 mM    NaCl 
 2.5 mM   KCl 
 
After autoclaving two filtrated solutions were added to sterilised medium: 
 10 mM    MgCl2 
 10 mM    Mg SO4 
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 TB-buffer 
 10 mM      PIPES, pH 6.7- KOH 
 15 mM      CaCl2 
 250 mM    KCl  
 55 mM      MnCl2   
was sterilised by filtration.   
 
3.2.7  Transformation of competent Escherichia coli 
About 200
 
µl of frozen competent Escherichia coli cells were thawed on ice. To the cells, 3-4 µl 
of ligation mixture or 10 ng of plasmid DNA was added. Mixtures were incubated on ice for 5-30 
minutes. Heat shock was performed by incubation at 42°C in a water bath for 90 seconds. After the 
heat shock, 1 ml of LB medium was added to the cells. Incubation for 30-45 minutes allows the 
expression of plasmid-encoded resistence genes. After that, the cells were pelleted (1 min 10 000 
rpm) in a benchtop centrifuge, resuspended in ~50 µl of LB medium and plated on selective plates. 
The plates were incubated overnight at 37°C.  
 
3.2.8 Amplification of DNA fragments via polymerase chain reaction (PCR) 
The polymerase chain reaction is a cyclic process, allowing in each cycle the duplication or the 
number of the DNA molecules (Mullis and Faloona, 1987). PCR was used in this work for isolation 
of genes from the yeast genome, site-directed mutagenesis and other modifications.  
In the first step of each cycle, double helices of template DNA are denatured by heating to high 
temperature (94°C). In the second step, the reaction mixture is cooled to 52-60°C, where the two 
oligonucleotide primers anneal on the template. The polymerization step heats the mixture to the 
temperature optimal for the DNA polymerase activity (72°C). At this step, the annealed primers are 
extended by DNA polymerization, the double helix is resynthesized in a template-dependent 
manner, the number of amplified molecules doubles. All these molecules can be substrates in the 
subsequent cycles  
Multiple repetition of these steps yields to an exponential increase of the amount of the template 
molecule fragments which are determined by the used oligonucleotide primers. 
Typical reaction:  
 1 µl of template DNA (~0.5µg of yeast genomic, or 10 ng of plasmid DNA) 
 1 µl of oligonucleotide #1 (50 µM) 
 1 µl of oligonucleotide #2 (50 µM) 
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                     10 µl of 10x  reaction buffer + MgCl2 (delivered by manufacturer) 
 2 µl of desoxynucleotide mix (10 mM each) 
 
  
                 84.5 µl of H2O 
              ---------------- 
              99.5 µl  
 
The reaction mixture was heated to 94°C for 3 minutes. During this step, 0.5 µl of DNA 
polymerase (Taq, DeepVent, or their mixture 5:1, depending on the application) was addet to 
reaction mixture.  
 
Typical cycling:  
 denaturation  30 sec  94°C 
 annealing   30 sec  52-60°C 
 polymerization x min 72°C (1min/1000 bases) 
 
Cycles described above were repeated 30 times. At the end of the whole reaction, an additional 
polymerization step, 72°C for 10 min, was applied.  
 
3.2.9 Methods for yeast genetics  
 3.2.9.1 Transformation of Saccharomyces cerevisiae 
For yeast transformation a modified method of (Ito et al., 1983)
 
was used. Treatment of yeast cells 
with alkaline cations leads to increased permeability of the DNA through the cell membrane, so that 
it is then taken-up by the cell. Cells can be transformed by linear DNA fragments that can 
subsequently integrate into the genome via homologous recombination (Rothstein, 1983). This is 
used widely for gene disruption of specific gene.  
100 ml of the appropriate yeast strain was grown in complete YEPG medium to OD600=0.5-1. 
The culture was centrifuged for 3 minutes at 2000xg and washed once with LiAc/TE solution. Cell 
pellets were resuspended in 1 ml of LiAc/TE solution. For transformation, 100 µl aliquot of cell 
suspension was mixed with an appropriate amount of DNA (<1 µg of plasmid DNA, 5-10 µg of 
linear DNA fragment for gene disruption or integration). After 5 minutes at RT, 280 µl of of 50% 
PEG4000 solution was added and the tube was incubated for 45 minutes at 30°C. Heat shock was 
performed by incubating at 42°C for 5 minutes. Cells were pelleted by centrifugation for 2 minutes 
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at 3000 rpm in a benchtop centrifuge, the supernatant was aspirated and discarded. The cell pellet 
was washed once with sterile H2O and resuspended in 200 µl of sterile H2O.  
Cells were plated on appropriate selective plates and incubated at 30°C for several days.  
LiAc/TE solution: 
 0.1M Li-acetate 
 10mM Tris.HCl pH 7.5 
 1mM EDTA  
 Sterilized by autoclaving 
 50% PEG4000 solution: 
 50% (w/v) PEG4000 in H20 
 Sterilized by autoclaving 
 
3.2.9.2 Measurement of yeast growth curves 
The required amount of yeast cells in the logarithmic phase of growth were washed with sterile 
water and used for inoculation of 100-200 ml of the appropriate medium to reach an optical density 
OD600 ~ 0.01. A new cell culture was inoculated at the appropriate temperature and the optical 
density was determined at regular time points. At an OD600 > 0.8, the culture was diluted with the 
same medium so that the measured OD600 value was lower than 0.8.  
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3.3   Biochemical Methods 
3.3.1 Determination of protein concentration according to Bradford (1976) 
The method is based on the observation that the protein dye Coomasie brillant blue G250 shifts its 
absorbance maximum from 465 nm to 595 when protein binding occurs. 990 µl of protein solution 
was mixed with 10 µl of dye solution (Sigma). After incubation for 5 minutes at RT, the absorbance 
at 595 was measured against a blank. A standard curve was determined using known concentrations 
of BSA. Protein concentration was read from the standard curve.  
3.3.2 Preparation of protein extracts of Saccharomyces cerevisiae for SDS 
polyacrylamide electrophoresis.  
Cells from a fresh liquid culture were pelleted by centrifugation at 5000xg for 5 minutes. The 
supernatant was discarded. The pellet was resuspended in 100 µl of lysis buffer per 1 OD600 unit 
and incubated on ice for 10 minutes. The proteins were precipitated by 1/10 volume of 100% (w/v) 
TCA. After 10 minutes of incubation on ice, proteins were pelleted by centrifugation in a bench 
centrifuge (10 min at 14 000 rpm). Protein pellets were washed briefly with larger amounts of a 1M 
Tris solution. After washing, the pellets were resuspended in 10 µl per 1 OD600 unit of Laemmli 
loading buffer and heated for 5 minutes to 95°C. Thus prepared samples were either loaded onto 
SDS gels or stored at -20°C until use.  
Lysis buffer:  
 2M NaOH  
 5% β-mercaptoethanol 
TCA solution:  
 100% (w/v) trichloroacetic acid 
Tris solution:  
 1M Tris base 
2x Laemmli loading buffer: 
 0.1 M Tris-HCl pH 6.8 
 2% SDS 
 2%  β-mercaptoethanol 
 20% glycerol 
 0.002% (w/v) Bromphenol blue 
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3.3.3 SDS polyacrylamide electrophoresis according to Laemmli (1970) (SDS 
PAGE) 
The samples were heated to 95°C for 5 minutes to denature the proteins by SDS binding and to 
disrupt the disulfide bonds by their reduction with β-Mercaptoethanol. Protein-SDS complexes 
possess a strong negative netcharge so that original charges of non-denatured proteins can be 
neglected. The charge density of all SDS complexes is approximately identical, so that  the proteins 
are separated mainly according to their mobility through gel matrix when an electrical field is 
applied.  
SDS PAGE was performed discontinuously, with stacking and separating gels. In the stacking gel, 
the glycine present in the running and loading buffers is not charged due to pH of the stacking gel. 
Therefore, the protein-SDS complexes move at the front and concentrate there. In the separating 
gel, glycine becomes negatively charged due to a change in the pH. It becomes a frontal ion and 
protein-SDS complexes separate behind it according to their size. The mobility of the protein is 
inversely proportional to the logarithm of its molecular mass. For the separation of larger proteins 
lower polyacrylamide concentrations in the separating gel were used  and, vica versa, for smaller 
proteins, a higher percentage of the gel matrix was applied. Electrophoresis was run at 25V/cm until 
the bromphenol blue tracking dye reached the bottom of the separating gel. The gels were either 
stained with staining solution or electroblotted onto a nitrocellulose membrane for subsequent 
immunoblotting. 
5x-Electrophoresis buffer: 0.125 M Tris base 
  0.96 M glycine 
  0.5 % (w/v) SDS 
 
5x-Laemmli loading buffer: 6.25 M Tris-HCl, pH6.8 
  2 % (w/v) SDS 
  10 % (v/v) glycerol 
  5 % (v/v) ß-mercaptoethanol 
  0.001 % (w/v) bromphenol blue 
 
Staining solution: 50 % (v/v) methanol 
  10 % (v/v) acetic acid 
  0.1 % (w/v) Coomassie Blue G-250 
 
Destaining solution: 10 % (v/v) acetic acid 
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Preparation of gels 
Gels were prepared in vertical arrangement between two glass plates separated by spacers. 
Separating gels of the required acrylamide percentage were poured immediately after 
polymerization was induced. The gel was overlayed by isopropanol and left to polymerize for 30-60 
minutes. Isopropanol was removed and separating gels were overlayed with stacking gels. The 
comb was inserted immediately (before the solution starts to polymerize). After polymerization for 
30 minutes, the gels were used or stored for further usage at 4°C. For analytical purposes, a Protean 
Minigel apparatus (BioRad), for preparative purposes a self-made apparatus was used.  
 
4 % Stacking gel (10 ml): 1.3 ml 30 % bis-acrylamide-stock solution 
  5.0 ml 0.25 M Tris-HCl, pH 6.8 + 0.2% SDS 
  3.6 ml H2O 
  75 µl APS 
  8 µl TEMED 
 
10 % Separation gel (10 ml): 3.3 ml 30 % bis-acrylamide-stock solution 
  5.0 ml 0.75 M Tris-HCl, pH 8.8 + 0.2% SDS 
  1.7 ml H2O 
  100 µl 10 % APS 
  3 µl TEMED 
   
12 % Separation gel (10 ml): 3.98 ml 30 % bis-acrylamide-stock solution 
  5 ml 0.75 M Tris-HCl, pH 8.8 + 0.2 % SDS 
  1.05 ml H2O 
  100 µl 10 % APS 
  3 µl TEMED 
14 % Separation gel (10 ml): 4.65 ml 30 % bis-acrylamide-stock solution 
  5 ml 0.75 M Tris-HCl, pH 8.8 + 0.2 % SDS 
  400 µl H2O 
  100 µl 10 % APS 
  3 µl TEMED 
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 3.3.4 Transfer of proteins from gels onto nitrocellulose filters,  
 Western blotting 
The gel with the separated proteins was washed with transfer buffer and put on soaked Whatmann 
paper. The gel was overlayed with nitrocellulose filter. Attention was paid not to introduce air 
bubbles. The whole sandwich was covered with two Whatmann papers, clipped in the holder and 
transferred to a chamber filled with transfer buffer. The cellulose filter aimed at the anode. The 
transfer was performed for 1 hour at a constant voltage of 100 V in the chilled chamber, or at 15 V 
overnight. 
The transfer of the proteins was controlled by staining the nitrocellulose membranes with 
Ponceau-red which stains the proteins reversibly. The membrane was incubated briefly with 
Ponceau solution and washed with water to destain.  
Transfer buffer: 20 mM Tris-base 
  150 mM glycine 
  20 % (v/v) methanol 
 
Ponceau solution: 40% (v/v) methanol 
 15%(v/v) acetic acid 
 2.5 g/l Ponceau-red 
filtered after Ponceau-red addition 
 
 3.3.5 Immunological detection of the proteins on the nitrocellulose  
  filters 
The nitrocellulose filter after Western blotting was incubated with 5% skim milk in TBST for 60 
minutes to saturate the protein binding sites on the membrane. Then the membrane was incubated 
for 1 hour with the primary antibody diluted in  TBST or 5% skim milk in TBST.  
The filter was washed for 3 x 10 minutes in TBST. Bound antibodies were labelled by a 30 
minutes incubation with a horse-radish peroxidase-coupled secondary antibody diluted 1:5 000. The 
filter was washed again as described above. The immobilized peroxidase was visualized by 
chemiluminiscence using the ECL System (Amersham) according to manufacturer's instructions. 
The chemiluminiscence was documented on ECL detection film (Amersham).  
 
TBST buffer:                           10mM   Tris-HCl pH7.5 
 0.9% (w/v) NaCl 
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 0.05% (v/v) Tween 20 
 3.3.6 Subcellular fractionation of yeast proteins by velocity   
  sedimentation on sucrose density gradients 
Membrane fractionation on 20-35 % sucrose gradients were done as described previously 
(Schroder et al., 1995). Cells were spheroblasted by treating with Lyticase in spheroblasting bufer at 
30º C for 1 hour. Formation of spheroblasts was controlled trough osmolisis in H2O (10µl per 
990µl) by spectrometry on 600 nm. The spheroblasts were lysed trough 30 passages by glass 
homogenisator in lysic buffer plus protease inhibitors then ceared twice for 5 min at 500 g in 2-ml 
reaction tubes.  1 ml of supernatant was   loaded onto an 11-ml sucrose gradient made up from 1-ml 
steps of 18, 22, 26, 30, 34, 38, 42, 46, 50, 54, and 60% (wt/vol) sucrose. The gradients were spun 
for 3 hours at 4ºC in SW-Ti rotor (Beckman) at 170,000 g. The gradient was then carefully 
collected into 12 equal fractions. Proteins were precipitated through incubation of probes with ice 
cold acetone in proportion 1:1 at -20ºC for two hours and following centrifugation on 14.000 g. The 
pellets were washed and resuspended in Laemmli loading buffer, resolved by SDS-PAGE and 
transferred to nitrocellulose and probed with antibodies. 
 
Spheroblasting buffer:  0.05 M NaH2PO7, pH 7.5 
  1.4 M Sorbitol    
  0.01 M NaN3 
  0.08 M β-mercaptoethanol  
Lysic buffer:   0.01 M Triethanolamin-hydrosulfat, pH 7.5 
  0.08 M Sorbitol 
  0.001 M EDTA 
  0.002 M MgCl2    
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3.3.7 Protein purification 
 3.3.7.1 Purification of humans recombinant His-tagged B-Raf proteins  
  from  Saccharomyces cerevisiae 
Recombinant proteins containing a 6xHistidine-tag can be purified by Ni-NTA (nickel-
nitrilotriacetic acid) chromatography which is based on the interaction between a transition Ni2+ ion 
immobilized on a matrix and the histidine side chains. Following washing of the matrix 
6xHistidine-tag fusion proteins can be eluted by adding free imidazole or EDTA or by reducing the 
pH.  
B-raf or their 14-3-3 binding mutants were cloned into an yeast expression vector pYES2 
(Invitrogen) under the control of the GAL1 promoter. To purify B-RAF or their 14-3-3 binding 
mutants, the plasmids were transformed into the strain cI3 ABYS. The yeast cells were grown 
overnight in 500 ml SC-(ura-) medium by shaking at 30ºC. The expression was induced by growth 
in galactose-containing medium for 24 hours. For this the cells were harvested, washed with and 
resuspended in SGal (ura-) medium. After induction overnight cells were harvested and washed 
with lysic buffer. The pellets were taken to purification or frozen at 80ºC. 
For purification the cells were resuspended in 30 ml lysic buffer plus protease inhibitors. After 
disruption using a French pressure cell and removal of cell debris by centrifugation at 10000 g at 
4ºC, the supernatant was added to 500 µl pre-washed Ni-NTA Sepharose (Amersham 
Biotechnology). 
The probes were incubated by rotary for 2 hours at 4ºC, washed three times with 20 ml lysic buffer 
for 20 min by rotary. Protein was eluted in 300µl with 200-500 mM imidazole gradient. 
 Lysic buffer, pH 7.4 
 25 mM       Na2PO4 
 25 mM       NaH2PO4 
 150 mM     NaCl 
 10 mM       Na4P2O7 
 25 mM      β-glycerophosphate disodium salt 
 10%           glycerol 
 Protease inhibitors:   
  Leupeptin 10 µg/ml (20 mg/ml : 5 µl per 10 ml)  
  Aprotinin 10 µg/ml (5 mg/ml : 20 µl per 10 ml) 
  Pepstatin  1,4 µg/ml (0,7 mg/ml : 20 µl per 10ml) 
  PMSF 1mM  (200mM : 50 µl per 10ml) 
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 3.3.7.2 Purification of human recombinant GST-tagged C-Raf protein 
 from Saccharomyces cerevisiae 
 
The GST•Bind purification systems are based on the widely recognized affinity of glutathione-S-
transferase (GST•Tag) fusion proteins for immobilized glutathione. Proteins are quickly and easily 
purified to near homogeneity in a single chromatographic step. Glutathione-resin based 
purifications require that the GST domain is soluble and properly folded. The gentle elution 
condition (10 mM reduced glutathione) avoids target protein denaturation. 
The C-raf was cloned an yeast expression vector pEG-KT under the control of the GAL1 
promoter. The plasmids were transformed into the strain yeast strain cI3 ABYS. The yeast cells 
were grown overnight in 500 ml SC-(ura-) medium by shaking at 30ºC.  The expression was 
induced by growth in galactose-containing medium for 24 hours. For this the cells were harvested, 
washed with and resuspended in SGal (ura-) medium. After induction overnight cells were 
harvested and washed with lysic buffer. The pellets were taken to purification or frozen at 80ºC.  
For purification the cells were resuspended in 30 ml lysic buffer + protease inhibitors. After 
disruption using a French pressure cell and removal of cell debris by centrifugation at 10000 g at 
4ºC, the supernatant was added to 250 µl pre-washed GST- Sepharose (Qiagen). 
The probes were incubated by rotary for 2 hours at 4ºC, washed three times with 20 ml kinase 
buffer for 20 min by rotary. Protein was eluted in 300 µl with 20 mM Glutathione in kinase buffer.
 
   Lysic buffer
 
 50 mM       Tris, pH 7.4 
 150 mM     NaCl 
 10 mM       Na4P2O7 
 25 mM       β-glycerophosphate disodium salt 
 10%            glycerol 
 Kinase buffer 
 25 mM       Hepes, pH 8.0 
 150 mM     NaCl 
 10 mM       Na4P2O7 
 25 mM      β-glycerophosphate disodium salt 
 10%            glycerol 
  Protease inhibitors: 
 Leupeptin 10 µg/ml (20 mg/ml : 5 µl per 10 ml) 
 Aprotinin 10 µg/ml (5 mg/ml : 20 µl per 10 ml) 
 Pepstatin  1,4 µg/ml (0,7 mg/ml : 20 µl per 10ml) 
 PMSF 1mM  (200mM : 50 µl per 10ml) 
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 3.3.7.3  Purification of human recombinant GGA3 protein from 
Escherichia coli 
The GST purification system is based on the affinity of glutathione-S-transferase (GST•Tag) 
fusion proteins for immobilized glutathione. After washing steps of the matrix GST-tag fusion 
proteins can be eluted by adding free glutathione. 
The BL21 E. coli cells were transformed with pGST-GGA3 plasmid, then inoculated in  50 ml LB 
medium and grown overnight at 37ºC by shaking. On the next morning this culture was diluted in 
proportion 1:20 in 900 ml LB medium and cultivated for 90 min at 37ºC by shaking.   The 
expression was induced by incubation with 0.1 mM IPTG for 3 hours at 37ºC by shaking. 
After that the cells were harvested, washed once with lysic buffer without TritonX-100 (TX-100) 
and resuspended in 8 ml lysic buffer. The cell suspension was sonicated 3 times for 15 sec and 
clarified by centrifugation at 10000g at 4ºC. To the collected supernatant 1.5 ml Glutationsepharose 
(Qiagen) was added and incubated by rotary at 4ºC for 2 or more hours. 
Then the beads were washed 2 times with buffer A and 2 times with buffer B. after that the beads 
were resuspended well with 3.7 ml buffer B plus 0.3 ml glycerol and store at 4ºC.  
About 20-50 µl of beads were run on the gel and quantify by Coomassie. Approximately 20 µg 
GST-GGA3 protein was used per pull down experiment. 
  Lysic buffer: 
  1· PBS 
  10 mM EDTA 
  1% TX-100 
  1mM DTT 
 Protease inhibitors: 
 Leupeptin 10 µg/ml (20 mg/ml : 5 µl per 10 ml) 
 Aprotinin 10 µg/ml (5 mg/ml : 20 µl per 10 ml) 
 Pepstatin  1,4 µg/ml (0,7 mg/ml : 20 µl per 10ml) 
 PMSF 1mM  (200mM : 50 µl per 10ml 
  Wash buffer A 
  1· PBS 
  300mM NaCl 
  0,5% TX-100 
  1mM DTT 
  + protease inhibitors: see above  
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  Wash bufer: B 
  PBS 
  0,5% TX-100 
  2mM MgCl2 
  1mM DTT 
  + protease inhibitors: see above 
 
 3.3.8  GGA3 pulldown assay  
Activated ARF6•GTP was monitored by binding to its effector GGA3 as described previously 
(Martinu et al., 2004). Briefly, COS7 cells were co-transfected with HA-ARF6 plus indicated 
plasmids using jetPEI and grown for 24 h. EGF stimulation was performed after 24 h starvation in 
0.03% serum with 100 ng/ml EGF (Cell System Biotechnologie Vertrieb) for 10 min at 37°C. 
Clarified lysates were incubated with 25 µg of GST-GGA3 immobilized on glutathione-Sepharose 
beads for 2 h at 4°C. The beads were washed three times with PBS, resuspended in SDS PAGE 
loading buffer and boiled. Bound proteins were size-fractionated by SDS-PAGE and detected by 
immunoblotting.     
 
 3.3.9   Immunoprecipitation of GFP-AR149 and ARF6 
COS7 cells were transfected with GFP-AR149 and HA-ARF6wt, HA-ARF6(Q67L) or HA-
ARF6(T27N) respectively with jetPEI (Biomol). After 24 h, cells were lysed in ARF6 lysis buffer 
(50mM Tris-HCl pH 7.0, 2mM MgCl2, 100mM NaCl, 10% Glycerol, 0.75% NP-40) containing 
protease inhibitors. To avoid high signal from heavy and light chains of antibodies on the Western 
blot we used Mouse IgG TruhBlot Set (NatuTec) including beads and secondary HRP-conjugated 
antibody. The clarified lysates were divided into two equilibrated parts, each of them was incubated 
for 2 h at 4°C with anti-GFP or anti-HA antibody respectively (Santa Cruz Biotechnology, USA). 
Next, the probes were precipitated with mouse-TruhBlot agarose (NatuTec) for 1h at 4°C. Beads 
were washed three times in the lysis buffer with 0.2% NP-40 and protease inhibitors.  
 
  3.3.10  In vitro kinase activity assay 
The kinase activity of an enzyme can be measured in vitro by the binding of phosphor from ATP 
by its substrate, so called phosphorylation reaction. In this work it was used the method for RAF 
proteins kinase activity detection  based on following phosphorylation of recombinant MEK1 and 
Erk2, detected using an activation-specific Erk antibody that recognizes Erk only when specifically 
phosphorylated by RAF on Y202 and Y204. 
 62 
The purified recombinant RAF kinases are stored at -80ºC, shawed directly for application and 
stored for short time on the ice. For reaction the following master mix was prepared: 
 5 µl 10 x kinase buffer   -------- 250 mM       Hepes, pH 8.0 
 0,5 µl MgCl2 (1 M)   1,5 M           NaCl   
 1 µl DTT (100 mM)   250 mM       β-glycerophosphate disodium salt 
 3 µl MEK (1 mg/ml)    100 mM       Na4P2O7        
 3 µl Erk    (1 mg/ml) 
 _ _ _ _ _ 
 12.5 µl per sample 
To this mix was added: 
 dd H2O to hole volume of reaction 50 µl 
 3 µg RAF protein 
 5 µl ATP (10 mM) to induce the kinase reaction 
The mixture was immediately incubated at 30°C for 30 min by shaking at 1200 rpm. The reaction 
is then stopped by adding of 20 µl 4 x SDS-loading buffer and incubated at 95°C for 5 min. The 
proteins are separated by SDS-PAGE and then blotted onto nitrocellulose membranes. Western blot 
is performed using phospho-specific pERK antibodies. Equal loading of the purified kinase is 
subsequently controlled by immunoblotting with specific antibodies. 
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3.4  Fluorescence Microscopy 
Fluorescence microscopy was done with an Openlab software (Improvision, UK) controlled 
inverted DMIRBE microscope (Leica, Germany) with Leica oil immersion objective. All images 
were captured and stored as Openlab LIF files. Images were subsequently processed using 
Photoshop software. 
 3.4.1 Yeast cell imaging 
  3.4.1.1  Yeast live cell imaging  
Yeast cells were transferred into a self-made chamber slide for imaging.  
Yeast vital visualising of vacuoles and endocytic compartments with FM4-64 dye. 
This method allows visualisation of vacuoles and endocytic compartments in yeast with FM4-64, 
N-(3-triethylammoniumpropyl)-4- (p-diethylaminophenyl-hexatrienyl) pyridinium dibromide,  
a lipophilic styryl dye, that is taken up by yeast cells via the endocytic pathway. Endocytosis of 
FM4-64 was modified from the protocol descriebed by Vida and Emr (1995). 
Yeast strains were grown in SD-medium to an optical density OD600 of 0.5. Cells were harvested 
and resuspended at 3-5 OD U/ml. FM4-64 (16 mM in DMSO) was added to the cells at a final 
concentration of 40 µM. Cells were then incubated in the presence of the dye for 5 min on ice. After 
this internalisation step, the yeast cells were washed three times in ice-cold medium to remove 
surface-bound dye. The cells were resuspended in SC-medium and incubated for various times at 
30ºC. Stained cells were placed on slides and visualised using optics (see above) 
  3.4.1.2  Fixed yeast cells imaging  
Cells were fixed in 3.7% paraformaldehyde in PBS, washed and subsequently digested for 1 hour 
with lyticase (Sigma). After washing and mounting, samples were either stored at 4°C or processed 
for imaging.  
 3.4.2  Mammalian cells imaging  
Cells were grown on cover slips, treated with growth factors or serum as indicated and 
subsequently fixed in 3.7% paraformaldehyde, permeabilized with 0.1% Triton X-100. Stainings 
were performed with specific antibodies and fluorescently labeled secondary antibodies.  
 3.4.2.1 Indirect immunofluorescence after cytosol depletion 
HeLa cells were grown on coverslips overnight. After two washes with PBS cells were treated with 
0,05% digitonin in isotonic sucrose buffer for 4 min on ice (Galmiche et al., 2008). After digitonin 
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treatment, cells were fixed with 3.7% paraformaldehyde in microtubule-stabilizing buffer (MSB; 
0.1 M PIPES, pH 6.9, 2 mM MgCl2, 2 mM EGTA), washed and subsequently permeabilized with 
0,1% w/v Saponin in MSB with 0.5% BSA for 10 min. To stain non-cytosolic A-RAF, cells were 
incubated with anti-A-RAF antibodies (Santa Cruz, USA) in combination with anti β-Tubulin 
antibodies (Chemicon International) at concentration of 20 µg/ml in MSB buffer with 0,5% BSA 
and 0,1% Saponin at room temperature for 2 h. Unbound antibodies were removed by 3 washes 
with the same buffer. The coverslips were incubated with appropriate secondary antibody 
(conjugated to TRITC or CY5) diluted 1:200 for 1 h. After three washes with  MSB and brief wash 
with deionized water the coverslips were mounted using MOWIOL (Calbiochem, USA). 
 
 3.4.2.2 Transferrin internalization 
HeLa cells were grown on coverslips overnight, transfected with either GFP or GFP-fused 
AR149, ARF6(Q67L), ARF6(T27N) respectively for 48 h. 
The cells were pre-incubated in serum-free medium for 1h 37°C. For continuous Tfn uptake, the 
cells were incubated in internalization medium (HBSS medium plus 1% BSA) containing 5 µg/ml 
Alexa Fluor 546-conjugated human Tfn (Invitrogen) at 37°C for indicated time. After Tfn 
internalization the cells were extensively washed three times with ice-cold PBS and fixed with 3.7% 
PFA. 
 
 3.4.2.3  siRNA-mediated depletion of human A-RAF. 
For generation of A-RAF specific siRNA we used a self-producing approach using the “X-
tremeGENE siRNA Dicer Kit” (Roche). Using this method we prepare first double-stranded RNA 
from T7-flanked target sequence. In our case it was 3'- end located A-RAF coding region from 
”Human easyRNA resourse” (German Resource Center for Genome). Next we digested the product 
with Dicer enzyme and purified approximately 20 µg siRNA as a set of about 15 different siRNA 
for A-RAF. To note as a big advantage, this procedure could be repeated as and when required.   
Scramble siRNA was from QIAGEN. Transfection was carried out using 2 µg of siRNA mixture 
and 10 µl of “X-tremeGENE siRNA Transfection Reagent” (Roche) for 6-well culture plates, 
according to the instructions provided by the manufacturer. 
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4. Results 
4.1  RAF protein properties in Saccharomyces cerevisiae. 
4.1.1 RAF proteins purified from Saccharomyces cerevisiae in the   
  active, phosphorylated state associate functionally with both   
 hetero- and homodimeric forms of 14-3-3 proteins. 
To study the RAF proteins in yeast system, we prepared several vectors for galactose- or 
methionine-inducible expression of tagged or intact RAF proteins in Saccharomyces cerevisiae 
(controlled by GAL1 and MET-25P promoters respectively). These vectors were transformed into 
different strains of S. cerevisiae and the expression levels of RAF proteins were tested by 
immunoblotting. Unfortunately only strains depleted of key vacuolar proteases pep-4 and prb-1, 
could produce decent levels of RAF proteins. In other strains RAF proteins were not detectable 
most possibly due to degradation. Therefore all our experiments were performed in two yeast 
strains: cl3-ABYS-86 and BJ5459 and their derivates.  
Next, we purified GST-tagged RAFs from cI3-ABYS-86 strain and analysed them by SDS-PAGE 
and immunoblotting. Surprisingly, despite good expression, no GST-B-RAF was purified by 
affinity purification on glutathione beads, whereas A- and C-RAF could be purified under the same 
conditions.  Therefore, B-RAF was expressed as N-terminally His-tagged protein and purified using 
metal chelating Ni-NTA agarose.  
Purified GST-C-RAF and GST-A-RAF co-purified with a protein doublet of 33 and 35 kDa. The 
proteins of this doublet were identified by immunoblotting as yeast 14-3-3 homologues, Bmh1p and 
Bmh2p (Fig.4-1A). Importantly, budding yeast S. cerevisiae contains only these two 14-3-3 
homologues in its genome, which is significantly less than mammalian and plant cells that express 
7-14 isoforms of 14-3-3. It is known that 14-3-3 proteins function as dimers and most of 
mammalian isoforms preferentially associate with other isoforms to form heterodimers. With its 
two 14-3-3 isoforms, yeast provide a simple model system for functional studies of 14-3-3 
interactions with RAF kinases. The fact that yeast cells express higher levels of Bmh1p than Bmh2p 
let us presume that Bmh1p exists at least partially as a homodimer in vivo.  
To test whether RAF kinases associate functionally in vivo with both homo - and heterodimeric 
forms of 14-3-3 proteins we used cl3-ABYS-86 yeast and a BMH2 gene-depleted cl3-ABYS-86, 
∆bmh2 strain (prepared by S. Albert, this laboratory). After purification of B-RAF protein from 
wild type and BMH2-deficient yeast strains, the kinase activity of the isolated proteins as well as 
their association with 14-3-3 proteins were investigated. In this experiment, B-RAF variants 
mutated at single 14-3-3 binding sites (B-RAF S365A and S729A), as well double mutant (B-RAF-
S365/S729), were included as controls. Data presented in Fig. 4-1B document that wild type B-RAF 
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associates effectively with both hetero- and homodimeric forms of yeast 14-3-3 proteins. In case of 
BMH2-deficient strain, only wild type B-RAF, but none of its 14-3-3 binding mutants, was able to 
form a complex with Bmh1p homodimer. It can be concluded that both 14-3-3 binding sites of B-
RAF are required for its association with 14-3-3 homodimer (Fig 4-1B), whereas the C-terminal 14-
3-3 binding site suffices for binding of heterodimers. 
Kinase activities of B-RAF 14-3-3 binding mutants were comparable with that of wild type 
protein regardless whether only Bmh1p or Bmh1p/Bmh2p complex was present. Substitution of 
serines in the internal or C-terminal binding domain did not influence the activity of B-RAF 
considerably; only double mutant showed decreased kinase activity (Fig 4-1B). Consistently, both 
14-3-3 binding serines of B-RAF were phosphorylated in yeast unless substituted with alanine (Fig 
4-1B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-1. RAF kinases associate in vivo with both homo- and heterodimers of 14-3-3 in S. cerevisiae. 
A. GST-C-RAF associates with both 14-3-3 isoforms, BMH1 and BMH2. 
The GST-tagged C-RAF kinase isolated from protease-deficient S. cerevisiae strain cI3-ABYS-86 by 
glutathione-Sepharose affinity chromatography was resolved by SDS-RAGE and visualized by Coomassie 
staining. 
B.  B-RAF binds to homo and heterodimers  of 14-3-3 proteins.* 
 BMH2 gene was knocked-out by homologous recombination in protease-deficient S. cerevisiae strain cI3-
ABYS-86. Both, wild type and ∆bmh2 strains were transformed with pYES2-B-RAF and its variants that 
were mutated at the single 14-3-3 binding sites (substitution of serine 365 and 729 by alanine) or B-RAF 
mutant impaired in both 14-3-3 coupling domains. His-tagged B-RAFs were purified by Ni-NTA 
chromatography. Expression level of the B-RAF proteins and their phosphorylation status were determined 
by immunoblotting using B-RAF antibodies and corresponding RAF phosphospecific antibodies as 
indicated. Kinase activities were measured by a coupled kinase assay (KA) in the presence of recombinant 
MEK and ERK proteins as described in Methods. The kinase dead variant of B-RAF (B-RAF-K483M) 
served as negative control and did not reveal any catalytic activity in yeast. These experiments were repeated 
three times and performed in cooperation with PhD S. Albert (University of Wuerzburg).  
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4.1.2 Localization of human RAF proteins in Saccharomyces cerevisiae 
 
The initial aim of this work was to investigate in vivo the membrane assotiation of RAF isoforms. 
To this end, RAF proteins A-, B- and C-RAF fused to GFP were expressed under the control of the 
inducible MET25 promotor. The distribution of overexpressed RAF proteins in S. cerevisiae was 
analyzed by fluorescent microscopy. GFP-B- and GFP-C-RAF, as well as the GFP protein alone, 
showed homogenous distribution in the cytosol. Only GFP-A-RAF decorated punctuate structures in 
the periplasmatic area (Fig.4-2, upper panel). In addition, GFP-A-RAF was enriched on bud necks 
during cell division and on shmoo tips after pheromone stimulation (Fig. 4-2, lower panel). 
Subcellular fractionation experiments corroborated the imaging data. Using sucrose density gradient 
proteins were separated into three fractions: cytosol/vacuole, light membrane, such as Golgi and 
endoplasmic reticulum, and heavy membrane, such as plasma membrane. GFP protein alone was 
found exclusively in cytosolic/vacuolar fraction, GFP-C-RAF was predominantly enriched in light 
fractions, while GFP-A-RAF was concentrated in heavy membrane fraction (Fig. 4-3). This 
observation indicated that of the three human RAF isoforms only A-RAF localized to specific sites 
of plasma membrane in S. cerevisiae, which are polarized during cell division and mating reaction. 
Figure 4-2.  Localization of RAF isoforms in yeast. **   
RAF isoforms were expressed as GFP fusions in yeast. The cells were grown, fixed and imaged as 
descriebed in Chapter 3.4.1. Only GFP-A-RAF localizes to small dots in the cell cortex, which accumulate to 
the tips of small buds and to the necks of larger buds (upper row, left). Induced polarization of yeast by α-
factor leads to relocation of GFP-A-RAF to the tip of mating projections called shmoos (lower row, left). 
Arrows indicate localization of GFP-A-RAF to the punctuate membrane sructures, which are enriched on the 
bud neck and at the shmoo tips.  These experiments were performed in cooperation with PhD S. Albert 
(University of Wuerzburg) and PhD M. Becker (University of Wuerzburg). 
conf.= confocal 
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Figure 4-3. A-RAF is enriched in 
the heavy membrane fractions of 
yeast lysates. ** 
Cell lysates from yeast, 
overexpressing GFP, GFP-A-RAF 
or GFP-C-RAF, were loaded on 
the top of sucrose gradient and 
centrifuged at 100.000xg. 
Fractionated lysates were 
subjected to protein precipitation 
and resuspended in Laemli 
loading buffer. Equivalent 
volumes of each fraction were  
loaded on SDS PAGE and 
immunoblotted. Proteins were  
visualized with specific antibodies  
as indicated on the left A-RAF  
is the only RAF protein, which segregates into heavymembrane/particle fractions. GFP alone fused C-RAF 
segregated into cytosolic/vacuolar fractions. Distribution of yeast membrane markers is shown in the lower 
rows. This experiment was performed in cooperation with PhD S. Albert (University of Wuerzburg) 
 
  
  4.1.3 Two lipid binding domains in A-RAF mediate specific membrane 
  association in Saccharomyces cerevisiae 
To identify the A-RAF domains responsible for membrane association a mutational analysis was 
performed. To first narrow down the involvement of specyfic A-RAF domains GFP tagged C- and 
N-terminal deletions mutants were generated. The mutants overlapped to various degrees in the 
central region of the protein. In a second step GFP fused A-RAF point mutants were generated. The 
correct size and expression level of deletion mutants was monitored by Western blot analysis 
(Fig.4-5B). The subcellular distribution was analysed by epifluorescence microscopy. For 
schematic overview of all mutants used in this study and their subcellular localization please see 
Fig. 4-4. The analysis of the deletion mutants revealed that neither  the N-terminal or C-terminal  
deletion mutants of A-RAF showed wild type localization. The N-terminal mutants, including the 
CR1 and CR2, but not CR3 domains, were homogenously distributed on the plasma membrane 
(Fig.4-5A, bottom panel). In contrast, the C-terminal mutants, including CR3 and CR2domains, 
showed predominantly homogenous cytosolic distribution with rare single spots (Fig.4-5A, upper 
panel). Only two deletion mutants, C-88-606 and N-1-388, which both contained a part of the CR1  
gradient density 
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Figure 4-4. Schematic presentation of analysed wild type and  mutant RAF isotypes in yeast. **   
N- and C-terminal deletions or point mutations were expressed as GFP fusions in yeast. Staining patterns of 
mutants are shown on the right. The largest C- and N-terminal deletions showing the “wild type” localisation 
are 1-388 and 88-606. Lipid binding domains (see also Fig.4-6), are indicated by yellow boxes.  
 
domain, corresponding to so the called CRD, and a part of the CR3 domain, corresponding to the 
PA binding site in C-RAF, showed the punctuate  plasma membrane distribution similar to A-RAF 
wild type (Fig.4-5A, right panel). The previously published work by Johnson et al. 2005, showed 
that CR1 region (RBD + CRD) was specifically required for binding to PtdIns(4,5)P2. Thus, the 
deletion analysis reveals that two A-RAF domains were crucial for wild type localisation. The first 
one is the CRD domain on the N-terminus, participated in binding to the RAS protein and to PS/ 
PtdIns(4,5)P2  rich membrane. The second one exhibit a part of the CR3 domain, corresponding to 
PA binding domain in the C-RAF. The identified sites in A-RAF are conserved among of three 
RAF isoforms; therefore we based our point mutation analysis on the published data for C-RAF. 
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Figure 4-5. Localization patterns of C- and N-terminal deletion mutants. ** 
A. Cells expressing A-RAF deletion mutants were grown and fixed as descriebed in Chapter 3.4.1.  The 
smallest N-terminal deletion (88-606) and smallest C-terminal deletion (1-388) retain wild type distribution. 
C-terminal deletions that lost the presumptive PA binding motif, while retaining the PtdIns(4,5)P2 binding 
motif in CRD (see the scheme above) are homogenously distributed to the plasma membrane. N-terminal 
deletions which possess only the PA-binding domain showed homogenous distribution with rare single spots 
(indicated by arrows). Magnification 100×. 
B. Immunoblot analysis of GFP-A-RAF deletion mutants 
Yeast cell lysates expressing indicated GFP-A-RAF constructs were subjected to protein extraction, as 
described in Chapter 3.3.2, loaded on SDS PAGE and analyzed by Western blot with antibodies against 
GFP.  
 
Two lipid binding domains were demonstrated to be crucial for C-RAF association with plasma 
membrane (marked with yellow color, see Fig.4-4). One of them in CRD domain was required for 
binding to phosphatidylserin (PS) (Hekman et al., 2002; Improta-Brears et al., 1999), the other one 
was crucial for binding to phosphatidic acid (PA) in CR3 (Hekman et al., 2002) (Rizzo et al., 2000). 
We generated the A-RAF point mutants in the sites, corresponding to PS and PA binding in C-RAF.  
Previously published data by Fabian at all, 1994, showed that conserved R89 located in RBD of all 
RAF isoforms was crucial for the binding of C-RAF to RAS on the plasma membrane. Since the 
membrane localization pattern of A-RAF, as well as of its minimal N-terminal mutant AR149, may 
be mediated by protein-protein interactions with yeast RAS protein family members, a point 
mutation converting R to L at position 52 in A-RAF was introduced. The microscopy examination 
of cells expressing this mutant showed, that in both  A-RAF_R52L and AR149_R52L the 
membrane association was destroyed (Fig.4-6A). 
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Figure 4-6. Effect of 
specific point mutations 
on RAF membrane 
localization. ** 
A. A point mutation in the 
RAS binding domain, 
which is crusial for RAS-
RAF interaction, disturb 
the  membrane assotiation 
of AR149 and A-RAF. 
Basic residue in the RAS 
binding domain (R52)  
was replaced with leucine 
and subcellular 
distribution of mutant 
GFP fusion protein was 
inspected by microscopy. 
Arginine at position 52 
(R52) has replaced by 
leucine, and the 
subcellular didtribution of 
the mutant GFP fusion 
proteins was inspected.  
R52L mutation, 
dislocated AR149 and A-
RAF to the cytosol, with rare punctuate spots (indicated by arrow) in the case of full length A-RAF. 
B. Mutations in two presumable lipid binding domains mimic the distribution of the C- and N- terminal 
deletion mutants. 
Replacement of R359 and K360 with alanine in the C-terminal lipid binding domain (corresponding to the 
phosphatidic acid binding domain of C-RAF) results in  a subcellular distribution that recembles the  
distribution of the deletion mutants, which lost this domain (for ex. AR149) (left). Mutation of R103 and 
K104 in CRD (corresponding to PS binding domain of C-RAF) fully dislocated the protein into the cytosol 
with typical rare punctuate spots, indicated by arrows.  
 
The substitution of the key basic residues of these lipid binding sites to alanine mimics the deletion 
of the C- or N-terminus respectively. Thus, A-RAF with a mutated PS binding site showed  
homogenously cytosolic distribution with some rare spots. Correspondingly, A-RAF with mutated 
PA lipid binding sites, showed homogenous distribution on the plasma membrane (Fig.4-6B). 
Taken together, two lipid binding sites, PS/ PtdIns(4,5)P2  and PA, were responsible for the GFP-A-
RAF punctuate pattern in S. cerevisiae. 
 
 
 
4.1.4 AR149 expression inhibits yeast cell polarisation, actin polymerisation, 
 cell growth and endocytosis 
During the analysis of the A-RAF deletion mutants we noticed, that expression of several C-
terminally truncated mutants changed the cell shape from oval to round and about 20% of the cells 
expressing AR149 became bigger in size. We focused our attention on the minimal N-terminal 
deletion mutant, called AR149, and analyzed the effects of its expression in S. cerevisiae. 
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The changing of the cell shape by yeast, so called cellular polarisation, is a fundamental process 
during the life cycle of yeast. Polarisation is associated with actin polymerisation and the subsequent 
pronounced change in cell morphology. Actin polymerization/depolymerisation events are essential 
for cell division, mating reaction and membrane trafficking. The polymerized actin, so called cortical 
actin, can be visualized by incorporation of rodamine labelled phalloidin. 
The staining of cortical actin in the yeast cells which expressed A-RAF or AR149 brought two 
significant findings:  
a) A-RAF containing patches did not co-localize with cortical actin (Fig. 4-7A, left)  
b) the fraction of big round cells, that expressed high levels of GFP-AR149, was not stained by 
rodamin-phalloidin (Fig. 4-7A, right), which indicates that these cells did not contain 
polymerised actin.  
Next, we asked whether other actin-dependent processes are affected in AR149 expressing cells 
too. The pheromone induced mating reaction, expressed in so called schmoo formation, is a process 
in yeast that depends on actin polymerisation. Schmoo formation is characterized by the transition 
from oval cell shape to pear-shaped cell. The big round GFP-AR149 expressing cells did not show a 
mating reaction after α- factor stimulation, like control cells (Fig.4-7B).  
The actin dynamic is known to be essential for membrane invagination, endosome formation and 
following vesicle transport and vacuole fusion in yeast (Girao et al., 2008). Therefore, we proposed 
to test the endocytosis in the cells expressing AR149. For this aim the FM4-64 uptake assay was 
employed. FM4-64 is a lipophilic styryl dye, which is taken up by yeast cells via the endocytic 
pathway. In this assay it is possible to follow endocytotic processes from the plasma membrane to 
the vacuolar membrane, a process which is completed within 20min. The non transformed cells and 
cells, expressing GFP-A-RAF and GFP-AR149, were incubated with FM4-64 for 5 min on the ice to 
internalize the dye into the plasma membrane. Then, the cells were washed, resuspensed in the 
medium and incubated at 30ºC for indicated time. The microscopy examination of the control cells 
and cells expressing GFP-A-RAF showed the standard distribution of visualized vesicles stepwise at 
2 min to the plasma membrane (Fig. 4-7D, upper panel), at 6 min to internalized endosomes (Fig. 4-
7D, middle panel), and at 20 min at the vacuolar membrane (Fig. 4-7D, bottom panel). In the cells, 
expressing GFP-AR149, FM4-64 visualized the few conglomerated spots. The huge round cell on 20 
min depicted no FM4-64 fluorescent signal whereas its neighbouring small round cell contained only 
one big conglomerate of enocytosed FM4-64 (Fig. 4-7, middle column). These results suggested that 
yeast expressing GFP-AR149, but not GFP-A-RAF, were affected in endocytosis. 
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Figure 4-7. AR149 expression causes defects in yeast  physiology. **   
A. Cells expressing high amounts of GFP-AR149 do not form cortical actin. 
Cells expressing GFP-A-RAF or GFP-AR149 were grown and fixed as described in Chapter 3.4.1. 
Polymerized actin was visualized by Alexa Fluor 546-conjugated Phalloidin. Note that cells expressing 
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higher levels of GFP-AR149 but not of full length A-RAF (bright green cells marked with arrows) lost 
cortical actin pathes.  
B. GFP-AR149 expression inhibits ∝-factor induced shmoo formation. 
Cells transformed with pUG36-AR149 (right) or A-RAF(303-606) (left) were treated with ∝-factor for 2h. 
Note increased overall size and absence of shmoos in cells expressing GFP-AR149 
C. GFP-AR149 expressing cells have nuclear abnormalities. 
DNA of the nucleus and mitochondria was stained with DAPI. Morphology of nuclei of AR149 expressors 
varied from fragmented (b) to completely dispersed (e). 
D. FM-4-64 uptake is affected in AR149-expressing yeast. 
Yeast transformed with pUG36-AR149, pUG36-A-RAF and an untransformed control were incubated with 
lipophilic styryl dye FM4-64 for 5 min on ice, washed, resuspended in medium and incubated by 30ºC for 
indicated periods. Then the cells were immediately subjected to life cell imaging. Transition of the red 
fluorescence from periplasmic endocytic sites to vacuoles is clearly visible at 20 minutes in control 
untranformed cells as well as in cells expressing GFP-A-RAF.  In contrast, GFP-AR149 expressing cells 
show foulty endocytosis. At each time point the FM4-64 dye labels conglomerated membrane structures. 
(indicated by arrows). 
 
The analysis of nuclear morphology by DAPI staining in the fraction of large apolar cells showed a 
number of changes which ranged from fragmented nuclei (Fig.4-7C, b) to fully dispersed DNA 
(Fig.4-7C, e). The viability test showed that about 20% of the cells did not survive after induction of 
GFP-AR149 under MET25 promoter (mild conditions). This is in agreement with the number of 
large apolar cells. To analyse the effect of AR149 expression on cell cycle progression cells were 
first incubated under promoter repression condition (SD(ura-) medium). After dilution to the same 
optic density, protein production was induced by culturing the cells in medium lacking metheonine, 
SD (ura-met-) medium. Cell growth was monitored by determination of optic density at different 
time points after culture media replacement. The cells expressing GFP-AR149 grew slower 
compared to cells that expressed GFP or GFP-A-RAF (difference in duplication time about 28 min) 
(Fig.4-8A). In conclusion, AR149 expression caused sustained cell growth inhibition in yeast.  
Next we asked whether higher expression levels of the AR149 mutant would lead to a more severe 
phenotype. For this aim we expressed proteins as GST fusions under control of the strongly inducible 
GAL1 promoter. As demonstrated in Fig. 4- 8B, cells transformed with either GST, GST-A-RAF or 
GST-AR149, grew expressing constructs well on repressive medium (with glucose as hydrogen 
sores). After induction of protein production (with galactose as hydrogen sores) GST-AR149 
expressing yeast cells did not grow (Fig.4- 8B). 
In summary, these experiments identified the minimal N-terminal A-RAF mutant (AR149), which 
localised homogenously to the plasma membrane in S. cerevisiae. The following analysis of AR149 
expression showed that AR149, but not A-RAF, blocks yeast cell polarisation, actin polymerisation 
and endocytosis, which lead to cell growth inhibition. 
An independent work from Yokoyama et al. (2007) discovered two C-terminal truncated splicing 
isoforms for A-RAF, called DA-RAF1 and DA-RAF2 in mammalian cells. One of them, DA-RAF 2, 
was nearly identical to our minimal N-terminal A-RAF mutant, AR149.  
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Figure 4-8. AR149 causes lethal 
phenotype in yeasts. ** 
A. Growth inhibition of AR149 expressing 
cells.  
Cells transformed with pUG36, pUG36-A-
RAF or pUG36-AR149 were grown under 
selective conditions in fresh selective 
medium. Cell proliferation was monitored 
by spectrophotometry. 
B. Lethality of GST-AR149.  
S.cerevisiae strain BJ 5459 was 
transformed with pEG-KT vehicle, 
pEG-A-RAF and pEG-AR149. 
Obtained colonies were streaked on 
uracil-dropout medium with glucose or 
galactose. Induction of protein 
production by galactose was lethal for 
GST-AR149 expressing cells, but not 
for these expressing either empty 
vehicle or full-length A-RAF.  
Both experiments were performed in 
cooperation with PhD S. Albert 
(University of Wuerzburg). 
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4.2 Study of A-RAF isoforms properties in mammalian cell lines 
 
4.2.1 AR149 and A-RAF intracellular distribution in mammalian cells 
The intrinsic strong phenotype of AR149 expressed yeast cells inspired to analyze the role of 
AR149 in membrane associated processes in mammalian cells. The first logical step was to 
investigate the subcellular localization of AR149 and A-RAF. HeLa cells were transiently 
transfected with GFP-AR149 and GFP-A-RAF encoding mammalian expression vectors. As controls 
GFP alone and a C-RAF N-terminal mutant, called RAF-C4 (Bruder et al., 1992), that corresponds to 
AR149, were used. As expected from yeast experiments, only GFP-AR149 was localized to the 
plasma membrane. Surprisingly, GFP-AR149 decorated also intracellular membrane structures, 
stretching through the cell body from the pericentriolar area to the plasma membrane. These 
structures were defined as “beads on a string” (Fischer et al., 2009) (Fig.4-11A). After nocodazole 
treatment, which caused depolymerisation of microtubules, these organised structures were destroyed 
(Fig.4-9A). In contrast to AR149, GFP-A-RAF and GFP-C-RAF-C4 showed nearly homogenous 
distribution in the cytoplasm (Fig.4-9A). The observed subcellular distribution of GFP-AR149 was 
not cell type specific since similar distribution was observed in the mouse fibroblast cell line NIH 
3T3, albeit without the pronounced tubular “beads on a string” structures (Fig. 4-10). These vesicular 
tubular structures most likely represented the recycling endosome compartment, which is known to 
be extended in HeLa cells (Robertson et al., 2006). One of the established markers for recycling 
endosomes is the ARF6 GTPase. Previous work by D'Souza-Schorey et al., 1995, showed, that 
ARF6 localizes to plasma membrane in its active state (GTP-bound) and to recycling endosomes in 
the inactive state (GDP-bound). During the changes in its state through regulatory proteins, GAPs or 
GEFs, ARF6 move from the plasma membrane to the recycling compartment and back thereby 
regulating membrane trafficking (see (D'Souza-Schorey and Chavrier, 2006) for review). The 
overexpression of ARF6 GTP-locked (Q67L), GDP-locked (T27N) or nucleotide-free (N121I) 
mutant forms different effects on the endocytic process (Robertson et al., 2006). 
Based on these data we hypothesized, that AR149 could be localized to ARF6-positive recycling 
compartments. To test this hypothesis co localization experiments were performed. To this end  
AR149 and A-RAF were fused to RFP. Microscopic analysis of HeLa cells overexpressing RFP-
AR149 confirmed the GFP-AR149 distribution. The full length RFP-tagged A-RAF could not be 
detected under these conditions, possibly because of aberrant folding of the fusion protein. The same 
phenomenon was observed when we tried  to express mCherry tagged A-RAF in yeast.Therefore, we 
used indirect immunfluorescence technique for detection of overexpressed Myc-tagged A-RAF.                   
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Figure 4-9. Localization of GFP-A-RAF and GFP-AR149 in mammalian cells. ** 
A. AR149 localizes to the tubular vesicular endosomes. HeLa cells were transiently transfected with pEGFP 
bearing the indicated genes for 2 days. GFP fusion proteins were detected by fluorescence microscopy. GFP-
A-RAF is present throughout the cytoplasm and accumulates around the nucleus. In contrast, GFP-AR149 
labels punctate structures often aligned on strings. Strings were disassembled by treatment with Nocodazole. 
A C-RAF fragment orthologous to AR149 is GFP-C-RAF(C4).  
B. AR149  and A-RAF colocalizes with ARF6 independently from its GTP·GDP- loading state·in HeLa cells.  
HeLa cells were cotransfected with RFP-AR149 and GFP-ARF6 as described above. RFP and GFP 
fluorescences were recorded separately. RFP-AR149 was cotransfected with GFP-ARF6, dominant active 
GFP-ARF6(Q67L) or dominant negative GFP-ARF6(T27N)  and inspected by fluorescent microscopy. High 
degree of colocalization with both ARF6 mutants is documented in overlay figures. 
 
A large fraction of exogenously expressed A-RAF distributed homogenously in the cytoplasm. 
To visualize the membrane associated fraction of A-RAF, depletion of the cytosol was achieved 
through digitonin permeabilisation as previously described by Galmiche et al., 2008 . 
Colocalization experiments with GFP-ARF6 and RFP-AR149 showed that both proteins were 
localized to the same tubular vesicular compartment. A small portion of proteins was localized to the 
plasma membrane (Fig. 4-9B, upper panel). This pattern led us to propose that AR149 could be able 
to shift ARF6 from plasma membrane (GTP-loaded state) to recycling endosomes (GDP-loaded 
state). We hypothesized that AR149 has a dominant negative effect on ARF6 activity. 
Two ARF6 nucleotide loading mutants GFP-ARF6_Q67L and GFP-ARF6_T27N (see above) were 
generated and included in the colocalization analysis. As demonstrated in Fig.4-9B, middle panels, 
RFP-AR149 colocalized with both GFP-ARF6_Q67L and GFP-ARF6_T27N on different subcellular 
compartments. The active GFP-ARF6_Q67L mutant localized to the plasma membrane. Typically, 
microvilli formation and  macropinocytotic vesicles were observed under these conditions. In the 
case of GDP-locked ARF6 mutant (T27N), RFP-AR149 colocalized with ARF6_T27N on 
intracellular vesicles. In conclusion, RFP-AR149 was found to localize into the ARF6-positive 
membrane compartments, independent from ARF6 nucleotide loading state.  
Analysis of the Myc-A-RAF distribution pattern showed that membrane-bound Myc-A-RAF 
colocalized with ARF6 on the plasma membrane and intracellular vesicles (Fig.4-9B, lower pannel). 
In summary, AR149 and A-RAF localized to ARF6-positive membrane compartments, such as the 
tubular vesicular endosomes and the plasma membrane. 
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4.2.2. Reduction of stress fiber formation by AR149 in NIH3T3 cells 
One of the dramatic effects of high AR149 expression on yeast cell morphology was the fully 
depolymerised actin. To investigate this effect of AR149 on actin polymerisation in mammalian cells 
the mouse fibroblast cell line NIH 3T3 which shows well-developed actin stress fibers was 
employed. 
In this cell line overexpressed GFP-AR149 caused reduction of stress fibers labelled with Alexa-
546 tagged phalloidin (Fig.4-10). This result is in agreement with results obtained by Yokoyama et 
al. (2007). 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-10.  AR149 expression reduses stress fibers formation in  NIH 3T3 cells. ** 
NIH 3T3 cells were transfected with GFP-AR149 for 24 hours. After fixation, the polymerized actin was 
visualized with Alexa-546 conjugated phalloidin. Note the remarkable regression of actin stress fibers in the 
transfected cell.  
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 4.2.3 Localization of  endogenous membrane-bound A-RAF to   
 microtubule-associated vesicles 
Apart from new data about cellular distribution of overexpressed A-RAF isoforms (Chapter 4.2.1), 
we proposed that at least a part of endogenous A-RAF should be localized to endosomes. To detect 
this we developed a new protocol for A-RAF labelling with α-A-RAF rabbit antibody (SantaCruz). 
Three optimizing factors were induced into standard protocol:  
1) digitonin extraction of cytosol fraction of A-RAF, allowed to detect only membrane-bound 
A-RAF; 
2) cell permeabilization with mild detergent – saponin, instead of TX-100, which permitted to 
preserve sensitive lipid structures like endosomes; 
3) all steps, except digitonin extraction, were carried out in microtubule-stabilizing buffer, 
which allowed  to label unaffected microtubule network. 
Due to this special protocol we were able to detect endogenous A-RAF on vesicular structures, 
which were found to associate with the microtubule network. As demonstrated in Fig.4-11A, A-
RAF-positive vesicles localized to the cell periphery of the periplasmic area and to nearly each plus 
end of microtubule. Additionaly, these vesicles were lining microtubules to the perinuclear area. To 
confirm the specificity of the A-RAF antibody, the following controls were performed. First, cells 
with siRNA mediated abrogation of A-RAF were subjected to the staining conditions used to detect 
A-RAF-positive vesicles. Second, unspecific normal rabbit antibody, instead of the A-RAF antibody, 
was used in the analysis. Both approaches resulted in the loss of the punctuate/ vesicular staining 
while nuclear staining could still observed (Fig.15C). Therefore, we concluded that labelling of 
nuclei by A-RAF antibody was unspecific. 
The fluorescent microscopy data were supported by biochemical fractionation. Thus, a big portion 
of GFP-AR149 and GFP-A-RAF was found in the cytoskeleton fraction (Fig.4-11B). 
Taken together, endogenous A-RAF localises to endosomal vesicles, associated with the 
cytoskeleton. 
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Figure 4-11. A-RAF associates with the cytoskeleton. ** 
A. Endogenous A-RAF  localizes to vesicles along 
microtubules. HeLa cells were treated with digitonin to extract 
cytosol. After fixation and washing, immunofluorescence 
microscopy with antibodies against A-RAF and β-tubulin was 
carried out. Small A-RAF positive vesicles are located at the 
periphery and line microtubules (indicated by arrows).  
B. AR149 and A-RAF are enriched inthe  cytoskeleton fraction. 
Cells were fractionated using “ProteoExtract Subcellular 
Proteome Extraction Kit“ (Calbiochem) and analyzed by 
immunoblotting. Antibodies against following proteins were 
used as compartmental markers: vimentin as cytoskeletal 
marker, PARP as nuclear marker, 2MPK as cytosolic marker.  
Both A-RAF and AR149 are co-fractionating predominantly 
with cytoskeleton and cytosol. A small portion of AR149 was 
also found in plasma membrane fraction. 
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4.2.4 Overexpression of AR149 in HeLa cells inhibits transferrin trafficking on 
the level of recycling compartments. 
The data so far pointed to a possible role of AR149 in endocytosis in mammalian cells. To address 
this question transferrin (Tfn) uptake as an assay for endocytosis was performed.  The Tfn uptake 
assay was chose due to the following advantages: 
1) it is well established  
2) it is considered as classical model for the study of clathrin-dependent endocytosis; 
3) Tfn trafficking is known to be accomplished by an ARF6-dependent mechanism. 
Tfn is an iron binding protein participating in iron homeostasis, which is internalized upon binding to 
its receptor via a clathrin-dependent pathway. Subsequently, Tfn is transmitted to the recycling 
compartments in the pericentriolar area and is recycled back to the plasma membrane.  
First, uptake and recycling of Transferrin (Tfn) was analysed. To this end, Hela cells were 
transfected with GFP alone, as a control, and GFP-AR149. After 1 hour under starvation conditions, 
the cells were incubated in medium, contaning Alexa546-tagged Tfn, for the indicated periods 
(Fig.4-12).  
In concordance with published data, Tfn accumulated in the pericentriolar area after 30 min in 
control cells (Fig. 4-12, upper panel). On the contrary, enrichment of internalized Tfn in the 
pericentriolar area was vastly delayed in AR149 expressing cells (Fig.4-12, bottom panel), though 
Tfn internalisation was not impaired. This resulted in cells that were crowded with Tfn, which was 
distributed through out the cytoplasm and was strongly colocalized with AR149 positive vesicles. In 
conclusion, internalized Tfn was trapped in AR149 containing endosomes. To better understand in 
which endosomal compartment Tfn trafficking is blocked, we performed a triple colocalization 
experiment with early (EEA1) and recycling (ARF6 and RAB11) endosomal markers. Thus, we 
observed significant signal overlap of RFP-A149, Alexa647-Tfn and GFP-ARF6 as well as GFP-
RAB11 at different time points (Fig. 4-13). In contrast, under the same conditions no significant 
colocalization was detected with GFP-EEA1 (Fig. 4-14). 
In summary, AR149 expressing cells did not show defects in Tfn internalization and assignment to 
tubular vesicular recycling endosomes. At this level the transfer of Tfn to the TGN- associated 
recycling compartment was significantly blocked.  
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Figure 4-12. Expression of GFP-AR149 blocks trafficking of Tfn to the pericentriolar endosome 
compartment. ** 
GFP-AR149-transfected and control (GFP-transfected) cells were incubated with fluorescent Tfn for 
indicated times. Tfn containing vesicles accumulate in the pericentriolar area of control cells, but remain in 
the GFP-AR149 positive vesicles scattered throughout the cytosol of GFP-AR149 transfected cells. 
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Figure 4-13. AR149 causes accumulation of inernalized transferrin in ARF6 and RAB11 positive 
endosomes. ** 
HeLa cells were transfected with RFP-AR149 and either GFP-ARF6 or RAB11 as indicated. Uptake of 
fluorescent Tfn was examined after 30 and 60 minutes. Representative images show that Tfn is trapped by 
AR149 in GFP-ARF6 positive and in GFP-RAB11 positive vesicles. Enlarged areas are marked by boxes. 
Arrows indicate co-localization. Scale bar = 10 µm.      
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Figure 4-14. Tfn does not accumulate in EEA1 positive early endosomes in AR149 expressing cells. ** 
HeLa cells were transfected as indicated and used for Tfn uptake assays. Note that fluorescence of Tfn and 
EEA1 do not mark identical vesicles. Enlarged areas are marked by boxes. Arrows indicate co-localization. 
Scale bar = 10 µm.     
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4.2.5 A-RAF knock down and downstream cascade inhibition phenocopy the 
effect of AR149 expression on Tfn recycling 
A dominant negative effect of the N-terminal part of RAF, such as C-RAF-C4(Bruder et al., 1992) 
or DA-RAF(Yokoyama et al., 2007), on ERK signalling has previously been described. Since AR149 
was identical to DA-RAF2 isoform, we expected that AR149 also exerted a dominant negative effect 
on the mitogenic cascade. Therefore siRNA mediated depletion of A-RAF was expected to have the 
same effect as AR149 overexpression. Towards this end HeLa cells were transfected with this A-RAF 
siRNA and scrambled siRNA as control. The effectivity of A-Raf depletion was first analyzed by 
Western blot analysis of cell lysates. As documented on Fig. 4-15A, the amount of A-RAF protein 
was significantly reduced in A-RAF siRNA-treated cells. The expression of C- and B-RAF proteins 
was not affected. 
Figure 4-15. Specific 
depletion of A-RAF 
protein and mRNA by 
siRNA. **   
A. HeLa cells were 
treated with A-RAF 
specific or scrambled 
siRNA and subjected to 
Western blot analysis 
with antibodies against 
actin (loading control) and 
three RAF isoforms. A-
RAF is the only RAF 
isoform the amount of 
which decreased after 
siRNA treatment.  
B. HeLa cells were first 
treated with two different 
batches of A-RAF-
specific or scrambled 
siRNA. Afterwards, the 
RNA was reverse 
transcribed and used as a 
template for quantitative 
PCR with primers specific 
for A-RAF, DA-RAF2 
and Actin mRNAs. The 
ratio between the tested mRNA and actin mRNA was calculated from the qPCR data. From the diagram it 
can be concluded that A-RAF mRNA amount is decreasing significantly. DA-RAF2 mRNA was poorly 
expressed in these cells and its expression level did not change upon siRNA treatment. This experiment was 
performed in cooperation with PhD S. Albert (University of Wuerzburg) 
C. Controls of indirect immunofluorecent staining of endogenous A-RAF. HeLa cells were incubated with 
normal rabbit serum (left panel) or with A-RAF specific antibodies  after A-RAF knock-down with siRNA 
(right panel). In both cases periplasmic punctate structures (see Fig. 4-11A) disappeared, whereas nuclear 
staining remained.  
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Figure 4-16. siRNA mediated A-RAF depletion,  MEK inhibition and expression of ARF6(T27N) also 
block accumulation of Tfn in the pericentriolar endosome compartment. ** 
A. HeLa cells transfected with A-RAF siRNA, scrambled siRNA or treated with  MEK inhibitor UO126 
were subjected to Tfn uptake assay. Lack of accumulation of endocytosed Tfn in the pericentriolar 
compartment is similar to AR149-expressing cells (compare with Figure 4-12). Representative images are 
shown. Scale bar = 10 µm.  
B. HeLa cells were transfected with ARF6(T27N) before assay for fluorescent Tfn uptake.  ARF6(T27N) 
positive vesicles accumulate internalised Tfn. The pattern of distribution is similar  to that in A-RAF siRNA 
and to U0126 treated cells. 
 
Since the target sequences for siRNA silencing was located on the 3'-end of A-RAF and was 
therefore not present in the DA-RAF sequence, DA-RAF was also not affected as proven by semi-
quantitative RT-PCR analysis. (Fig.4-15B). Therefore, with this approach, we achieved highly 
effective and specific depletion of A-RAF on both, the protein and mRNA level. 
To test whether A-RAF silencing had any effect on endocytosis, HeLa cells, treated with A-RAF 
siRNA or with scrambled siRNA, as a control, were analyzed for Tfn uptake. The data clearly 
showed that A-RAF depletion resulted in redistribution of internalized Tfn similar to that caused by 
AR149 overexpression (Fig. 4-16). In conclusion, A-RAF kinase activity is required for normal Tfn 
trafficking. The chemical inhibition of the RAF down-stream effector – MEK by U0126, delayed the 
accumulation of Tfn in the pericentriolar area, which closely resembled the effect of siRNA 
mediated A-RAF silencing (Fig.4-16, middle panel). Of note, in both cases, the accumulated Tfn 
decorated tubular structures, reaching from the perinuclear area to the cell periphery. 
To investigate in which compartment in A-RAF depleted cells is Tfn trapped, A-RAF siRNA treated 
HeLa cells were analysed for Tfn uptake and subsequently, colocalization of internalized Tfn and 
ARF-6 and RAB11-positives vesicles was examined (Fig. 4-16). In the case of the early endosome 
marker, EEA1, no significant overlap with Tfn was detected (Fig.4-18), while Tfn colocalized with 
ARF6- and RAB11- positive vesicles were detected (Fig. 4-17).  
Due to the fact that the phenotypes of A-RAF knock down and inhibition of the mitogenic cascade 
overlapped, we conclude that localized ERK signalling, driven by A-RAF on the endosomes, is 
required for endosomal maturation. The splicing isoforms AR149/DA-RAF1,2 work as naturally 
occurring dominant negative inhibitors of A-RAF activity. 
 
 
  4.2.6 ARF6_T27N, like AR149, traps the internalized Tfn in the recycling 
compartment 
The ARF6 GDP-locked mutant, ARF6_T27N, corresponds to the inactive state of ARF6 has 
previously been shown to localize to the recycling compartment (D'Souza-Schorey et al., 1998). The 
effect of ARF6_T27N expression has been described as re-distribution of Tfn receptor and inhibition 
of Tfn recycling to the plasma membrane (D'Souza-Schorey et al., 1995). If the hypothesis, that 
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AR149 has a dominant negative effect on ARF6 activity (see chapter 4.2.1) was correct, an effect of 
ARF6_T27N expression on Tfn trafficking would have been expected.To this end, HeLa cells, 
expressing GFP-ARF6_T27N, were subjected to the Tfn uptake assay. As documented in the Fig. 4-
16B, Tfn accumulation in the pericentriolar area was affected in ARF6_T27N expressing cells. In 
addition, ARF6_T27N positive vesicles were colocalized with internalized Tfn.  
In summary, expression of ARF6_T27N, AR149 and siRNA mediated negative regulation of A-RAF 
signalling, as well as MEK inhibition, exerted similar effects on Tfn trafficking.  
Therefore, these data suggested that ARF6 and A-RAF are involved in the same regulatory step of 
endosome maturation. However, at this stage of the work, it was not clear, which epistatic 
relationship exists between A-RAF and ARF6. 
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Figure 4-17. Tfn accumulates in ARF6 positives, RAB11 positives vesicles after siRNA silencing of A-RAF. 
** 
HeLa cells were cotransfected with either GFP-ARF6 or GFP-RAB11 and A-RAF siRNA. Tfn uptake was 
assayed as before. Tfn was found to co-localize with ARF6 or RAB11 as was observed in AR149 expressing 
cells. Enlarged areas are marked by boxes. Arrows indicate co-localization. Scale bar=10 µm. 
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Figure 4-18.  Tfn trafficking is not blocked on the level of early endosomes in cells  with abrogated A-
RAF expression. ** 
HeLa cells were transfected as indicated and used for Tfn uptake assays. Note that fluorescence of Tfn and 
EEA1 do not mark identical vesicles. Enlarged areas are marked by boxes. Arrows indicate co-localization. 
Scale bar = 10 µm.      
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  4.2.7 AR149 is complexed with ARF6, independent of the ARF6  
  nucleotide status 
The immunefluorescent experiments, described above (Chapter 4.2.1) showed colocalization of 
AR149 with ARF6 and its nucleotide locked mutants (Fig.4-9B). Moreover, AR149 had a dominant 
negative effect on ARF6 cargo trafficking (Fig.4-12). As independent means to verify complex 
formation of AR149 and ARF6 an immunoprecipitation approach was used. To isolate the putative 
complex, GFP-AR149 was co-expressed with HA-ARF6, or HA-ARF6_Q67L, or HA-ARF6T27N in 
COS7 cells respectively. After cell lysis, the cell lysates were divided into two parts and 
immunoprecipitation was performed in two directions: AR149 was precipitated by α-GFP antibody 
and co-isolated ARF6 was detected by WB. In parallel, ARF6 was isolated by α -HA antibody 
precipitation and AR149 was detected by WB. To control the specificity of immunoprecipitation, 
combinations of the individual expression vectors were performed (Fig.19A, bottom). As shown in 
Fig. 4-19A, in both direction, AR149 and ARF6 was isolated in one protein complex. As expected 
from colocalisation experiment, this binding occurred with ARF6 as well as with its GTP- and GDP-
locked mutants, ARF6_Q67L and ARF6_T27N respectively. Thus, independent of its nucleotide 
status, ARF6 was biochemicaly show to be in one protein complex with AR149. 
 
    4.2.8 Activation of ARF6 is controlled by opposing function of  
   A-RAF and AR149 
Our interpretation of the results described above (4.2.2 and 4.2.4) was that AR149 could have a 
dominant negative effect on ARF6 activity.  To monitore ARF6 activity we made used of the 
specific interaction of GGA3 (an effector of ARF6) with the active, GTP-loaded, form of ARF6. 
Based on this property it was possible to use purified GST-tagged GGA3 as bait to pull down 
ARF6·GTP from cell lysates. First, method was standardized with control probes (Fig.4-19B). 
Immobilized on GSH-sepharose GST-GGA3 protein was incubated with cell lysates of COS7 cells 
with ectopical expression of either wild type (wt) ARF6, dominant active ARF6_Q67L or dominant 
negative ARF6_T27N. WB analysis of the pulled down material showed in Fig. 4-19B. As expected, 
the dominant active form, ARF6_Q67L, pulled most efficiently, wt ARF6 was pulled less efficiently. 
The dominant negative form was not pulled at all.  
Next, we stimulated starved COS7 cells with EGF, an activator of the mitogenic cascade. Under this 
condition, an increased amount of ARF6 protein was pulled by GGA3, in comparison to non-
stimulated cells (Fig. 4-19C). In contrast, coexpression of AR149 (Fig.4-19E) or A-RAF depletion 
by siRNA (Fig.4-19F) diminished the activation of ARF6 by mitogenic signalling.  
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Figure 4-19. Expression of AR149 or siRNA mediated depletion of A-RAF interferes with  
activation of ARF6. ** 
A. Interaction of AR149 and ARF6.   
COS7 cells were co-transfected with GFP-AR149 and either HA-tagged ARF6wt, GTP-locked 
[ARF6(Q67L)] or GDP-locked [ARF6(T27N)]. After immunoprecipitation with α-GFP antibodies, co-
 94 
precipitated ARF proteins were detected with α-HA antibodies. In the second experiment, precipitation and 
detection antibodies were exchanged.  
Expression levels in whole cell lysates (WCL) is shown in two bottom panels. Empty vectors were used for 
control (bottom panel). 
B. GGA3 interacts with ARF6•GTP. COS7 cells were transfected with wild type, GTP-locked (Q67L) or 
GDP-locked (T27N) HA-ARF6. Proteins pulled-down by incubation with GST-GGA3-Sepharose were 
detected with α-HA antibodies.  
 
C.,E. AR149 suppresses EGF-stimulated ARF6 activation.   
COS7 cells, transfected with either ARF6 alone or ARF6 + GFP-AR149, were treated with EGF for 10 min 
and subjected to GGA3 pull-down. Bound protein was analysed by immunoblotting. Note decrease in the 
amount of ARF•GTP by AR149 coexpression. AR149 remains in the pulled-down ARF6 complex confirming 
the immunoprecipitation data. 
D. AR149 inhibits ARF6 activation by EFA6. COS7 cells were transfected with HA-ARF6 and either 
AR149, EFA6, or both. ARF6•GTP was pulled-down by GST-GGA3. AR149 decreases EFA6-stimulated 
ARF6 activation. 
 
F.  ARF6 activation by EGF or EFA6 requires A-RAF. 
ARF6 activation was assessed by GGA3 pull-down. The amount of A-RAF and ARF6 protein were 
determed by Western blotting (WB). Treatment conditions are as indicated. 
 
The fact, that precipitated ARF6·GTP was complexed with AR149 (Fig.4-19E) excluded competitive 
binding of AR149 and GGA3 to ARF6.   
To gain further insight into the mechanism by which AR149 can inhibit ARF6 activity, the EFA6 
protein, as ARF6 exchange factor and activator (Martinu et al., 2004), was included in the analysis. 
As documented in Fig.4-19D, coexpression of AR149, EFA6 and ARF6 attenuated the activating 
effect of EFA6 on ARF6. Similary, A-RAF depletion caused reduced activation of ARF6 by EGF 
stimulation, which can partially rescue by EFA6 coexpression (Fig.4-19F). 
Together this data revealed a mechanism by which A-RAF as activator and AR149 as inhibitor of 
mitogenic signalling on endosomes can regulate ARF6 activity. Further this shows that the actual 
target of mitogenic cascade is ARF6 exchange factor EFA6.  
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5. Discussion 
5.1  Saccharomyces cerevisiae as a simplified model for studies of RAF 
signalling 
Budding yeast S. cerevisiae is an established eukaryotic model organism, which played a central 
role in the elucidation of basic cellular processes such as cell division (Nurse, 1985), intracellular 
trafficking (Novick et al., 1980) and signal transduction (Madhani and Fink, 1998). Despite the lack 
of RAF proteins, yeast has played an important role in RAF research, predominantly as a tool for 
the identification of interacting proteins by two-hybrid screening (Freed et al., 1994) (Hagemann 
and Rapp, 1999) (Yuryev and Wennogle, 2003, but also as genetic screens, where the absence of 
endogenous RAF kinases in yeast was successfully overcome, by a series of elegant genetic 
manipulations. Yeasts with deleted STE11 (MAPKKK) gene and bearing an activating STE7 
(MAPKK) mutation were shown to depend on exogenous RAF kinase activity. Using this system, 
Irie et al. identified the yeast RAS protein and 14-3-3 homologues (Bmh1p, Bmh2p) as activators of 
mammalian RAF kinase {Irie, 1994 #16). Of note, budding yeast S. cerevisiae contains only two 
14-3-3 homologues, BMH1 and BMH2, as compared with mammalian and plant cells that express 
7-14 isoforms. Thus, S. cerevisiae provides a simple model system for functional studies of 14-3-3 
interactions with other signalling molecules. 14-3-3 as adaptor proteins associate with 
phosphorylated RAF kinases through two highly conserved motifs, RSXpSXP, stabilize RAF 
conformation and participate in RAF activation. It was shown, that 14-3-3 isoforms form different 
homo- and hetero-dimers. These 14-3-3 dimer formation may have important role in RAF 
regulation. However, informations about 14-3-3 dimer specificity are very poor. Due to using of S. 
cerevisiae strain, containing only one 14-3-3 isoform, we were able to show in vivo, that BMH1 
homodimer was sufficient to activate B-RAF. Mutational analysis of phosphorylated serines reveal 
that both 14-3-3 binding sites of B-RAF were required for association with 14-3-3 homodimers. 
These data contribute to a new model of RAF regulation by adaptor proteins (Fischer et al., 2009). 
 
5.2 Unique properties of A-RAF kinase 
In this work we disclosed an unexpected link between A-RAF and ARF6-dependent endocytosis. 
A-RAF has a set of differences, which distinguish it from C-and B-RAF. First, A-raf gene location 
and regulation is unique. A-raf gene is the only RAF gene located in X-chromosome and its promoter 
region contains glucocorticoid-response elements (Lee et al., 1996), which contribute to steroid-
hormone regulation of A-RAF mRNA expression (Winer and Wolgemuth, 1995).    
Next, A-RAF protein possess a number of features making it different from other RAF proteins. 
First, A-RAF has the lowest amplitude of kinase activity, due to amino acid substitution in the N-
 96 
region, located immediately upstream of kinase domain (Baljuls et al., 2007). Moreover, the profile 
of activation process is distinct from that of C- and B-RAF. Earlier work showed that 5 min after 
hormone stimulation, A-RAF has a short kinase activity pick, similar to C-RAF, but with lower 
amplitude. Then A-RAF activity reaches a plateau of prolonged kinase activity, similar to B-RAF, 
but much longer (Wixler et al., 1996). These data are clarified by recently published work focusing 
on A-RAF regulation by phosphorylation. It was shown, that feedback phosphorylation by RAF 
downstream effector, ERK, has a positive effect on A-RAF activity (Baljuls et al., 2008), whereas on 
C-RAF it has an inhibitory effect (Dougherty et al., 2005) (Hekman et al., 2005). This fact could 
explain the prolonged kinase activity of A-RAF after groth factor stimulation. 
Pelkman et al. (2005) studied the role of human kinome with respect to different types of 
endocytosis. They found that knock down of A-RAF, but not B- or C-RAF, delayed the 
endocytosisof SV virus. In contrast, B- and C-RAF knock down accelerated it.  These data are in 
agreement with the model of A-RAF acting in the regulation of endocytosis as presented in this work 
(see Chapter 5.8). 
 
5.3 The role of lipid binding domains responsible for A-RAF/AR149 specific 
localization  
The first evidence for A-RAF specific lipid binding domains was achieved from intrinsic 
localisation of A-RAF in S. cerevisiae. After ruling out the co-localization with cortical actin 
patches, A-Raf localization in yeast clearly resembled that of some proteins, participating in 
regulation of actin polymerisation and endocytosis, such as Abp1p, Pan1p, Sla1p and Sla2p(Gourlay 
et al., 2003; Sun et al., 2007).                                                                               
Remarkably, all these proteins bind to PtdIns(4,5)P2 -rich membranes, which could be labelled by 
expression of fluorescent sensor. Pleckstrin homology (PH) domain of PLCδ fused to GFP (GFP-
PLCδPH) was described to visualize PtdIns(4,5)P2  -rich membrane(Falasca et al., 1998). However, 
when expressed in S. cerevisiae, GFP-PLCδPH showed homogenous plasma membrane distribution 
instead of a patchlike one (Stefan et al., 2002). Another work identified a new sensor, which 
effectively labelled PtdIns(4,5)P2 – rich membrane domains in yeast – so called AP180 N-terminally 
homology (ANTH) domain (Itoh et al., 2001). 
Based on these data, we conclude that both A-RAF and AR149 bind to PtdIns(4,5)P2  -rich 
membrane domains. The differences in localisation between A-RAF and AR149 could have two 
reasons. First, A-RAF possesses a second lipid binding domain on the C-terminus, which contributes 
to A-RAF membrane distribution. Second, GFP-AR149 binds the PtdIns(4,5)P2  with higher affinity, 
which similar to GFP-PLCδPH, showed homogenously plasma membrane distribution, when highly 
expressed in yeast. 
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Our data are in concordance with biochemical data from Johnson et al. (2005), that showed that 
only A-RAF binds to immobilized PtdIns(4,5)P2 in vitro. Mutation analysis of A-RAF revealed RAS 
binding domain as crucial for PtdIns(4,5)P2 binding, which partially supports our data. In our 
experiments  substitution of R52 to L in A-RAF or AR149, which is known to disrupt binding of C-
RAF to RAS, disturbed its plasma membrane localisation. In contrast, our deletion analysis showed 
that CRD domain was sufficient for membrane localization of A-RAF and mutant lacking RBD 
domain (88-606) still bound the membranes. 
Based on these facts we map the PtdIns(4,5)P2 binding site in A-RAF to the CRD domain. The 
conflicting data with the R52L mutant we interpret as an indirect effect. We suppose that the R52L 
mutation in RBD could causes conformational changes in the CR1 conserved region. Given the 
known cooperation of RBD and CRD by binding to RAS (Drugan et al., 1996) it is conceivable, that 
the mutant RBD can  prevent binding of CRD to PtdIns(4,5)P2.  
 In this work we localized A-RAF/AR149 to ARF6-positive endosomal compartment. 
Interestingly, ARF6 GTPase, among other functions, regulates also metabolism of PtdIns(4,5)P2. 
Thus, synergistic activation effect of ARF6 on PIP5K and PLD activity could lead to a large increase 
of the PtdIns(4,5)P2 level at the cell periphery. 
 
5.4 Possible mechanism of AR149 dominant negative effect in S. cerevisiae 
On the stage of RAF investigation in yeast heterologous system we could not really define by 
which mechanism the dominant negative effect is provided. In general, there were two possibilities 
of AR149 working: strong association with proteins or with lipids and affecting their normal 
function. Apart from possible interference of AR149 with one of 6 yeast MAP pathways, proteins 
from two other signalling cascades were in the running: mating-pheromone response and 
filamentation-invasion pathways. The mating-pheromone pathway is more related to mitogenic 
cascade in mammals, but is not triggered by RAS protein. S. cerevisiae has two RAS isoform: Ras1p 
and Ras2p, which are involved in filamentation-invasion pathways. Double knock out of RAS genes 
is viable. Both cascades include the same MAP kinase module (Ste11p-Ste7p-MAP), except for 
MAP kinase. For the mitogen cascade Fus3p is an effector of transcription factor activation, wich 
initiates mating reaction. A second MAP kinase Kss1, on the other hand, is characterized by 
formation of so called pseudohyphae. The pseudohyphae are formed at the edge of colonies. They 
consist of filaments of extended and connected cells, that invade solid medium. This effect is 
induced under specific nitrogen starvation conditions by diploid yeast, but haploid strains can be also 
induced to invade solid medium (reviewed by (Gustin et al., 1998)). So, it is still an open question 
whether AR149 effect is mediated by affecting RAS function or wether some other unknown 
proteins become disregulated by AR149 expression. 
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On the other hand, AR149 can bind directly to the PtdIns(4,5)P2 (s. chapter 5.3) and block the 
processes, regulated by this lipid messenger, such as actin polymerisation and endocytosis (Sun et 
al., 2007). Only the experiments in mammalian cells provided clear evidence, that ARF6-GTPase is 
target of AR149, which links the mitogenic cascade to regulation of PtdIns(4,5)P2 production, actin 
polymerization and endocytosis.  
In yeast the functional homolog of ARF6 is Arf3p, which was recently shown to regulate actin 
polymerisation (Lambert et al., 2007) and PtdIns(4,5)P2 level at the plasma membrane (Smaczynska-
de Rooij et al., 2008) and facilitate membrane trafficking. Thus, we conclude that dominant lethal 
phenotype of AR149 is most probably mediated by the interference with Arf3p function. 
 
5.5 A-RAF and AR149 localize to endosomes 
The striking localisation pattern of A-RAF isoform to punctuated structures in yeast resembled that 
in mammalian cells. In yeast, A-RAF localisation to cortical patches represents distribution of Sla1p 
and Sla2p, which binds to both activators of protein dynamics, Abp1, Las17p/WASP and Pan1, and 
to cargo proteins. Moreover, this complex includes Arf3p (homolog of ARF6) and localizes to 
PtdIns(4,5)P2 –rich membrane domains (Costa and Ayscough, 2005). The AP180/Pan1p complex 
localizes to cortical actin patches and participates in early steps of endocytosis. These steps in 
endocytosis seem to be conserved among eukaryotes. Their homologues in mammals, so called 
E/ANTH proteins, such as HIP1/Sla2p and CALM/AP180, possess protein-protein and protein-lipid 
interaction domains, stabilizes clathrin coats and provide links between endocytic membranes and 
microtubules (Legendre-Guillemin et al., 2004). Localization of endogenous A-RAF on the tip of 
microtubules resembled that of cytoplasmic linker protein 170 (CLIP-170) (Akhmanova and 
Hoogenraad, 2005), a plus-end tracking protein, which together with regulation of microtubule 
dynamics, connects microtubule plus-end and specific sites of cortical actin and, what is most 
important for  us, captures cargos for motor-dependent movement. According to the current view, 
CLIP-170 first recruits dynactin to the microtubuli plus-end. Dynactin is a large adaptor protein, 
which on the one hand associates with microtubules, on the other hand links the motor protein 
dynein to its membrane-based cargos. Through LIS1-dependent uncoupling of dynactin from CLIP-
170 the movement of dynein-dynactin-vesicle complex towards the microtubule-organizing-centre 
(MTOS) begins (Wu et al., 2006). Interestingly, a connection between CLIP-170 and ERK was 
documented: IQGAP1 protein is found to interact with CLIP-170 (Fukata et al., 2002) and ERK2 
(Roy et al., 2004). 
Unfortunately, it is technically impossible to label endogenous A-RAF under live conditions to get 
eventually some time-lapse movies of A-RAF positives vesicles. Nevertheless, the unique particular 
distribution of membrane-bound A-RAF to the vesicles on the tip along microtubules let us speculate 
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on involvement of A-RAF-driven mitogen signalling in to cytoskeleton-associated motor-dependent 
vesicular trafficking. 
The localization of AR149 to the tubular vesicular endosomes seems to be caused by tight 
interaction with PtdIns(4,5)P2 and ARF6.Consistently, this localisation was sensitive to microtubule 
destabilization by Nocodazole. It is conceivable that AR149 localizes to recycling endosomes per se, 
whereas A-RAF localizes to endosomes in all stages of endosome maturation. 
 
5.6 Involvement of A-RAF and AR149 in vesicular trafficking  
The fact, that AR149 overexpression traps the internalized Tfn in ARF6- and RAB11-positive 
recycling compartment and mimics thereby the effect of dominant-negative mutant of ARF6 (T27N), 
required the clear definition of all steps of Tfn uptake. In our work we employed as a standard the 
definitions of (D'Souza-Schorey et al., 1998). According to this view, Tfn, bound to Tfn receptor at the 
plasma membrane is first internalized by clathrin-dependent mechanism and relocated into early 
endosomes. Following endosome maturation Tfn is led through tubulo-vesicular recycling endosomes 
to the pericentriolar TGN-associated recycling endosomes and, finally, is recycled back to the plasma 
membrane. All these steps are dependent on ARF6 GTPase activity. Dominant active mutant, 
ARF6_Q67L, prevents the internalisation of Tfn, whereas its dominant negative mutant, ARF6_T27N 
causes redistribution of internalized Tfn from pericentriolar recycling compartment (D'Souza-Schorey 
et al., 1995). In our work we demonstrated, that expression of AR149 or siRNA silencing of A-RAF 
resulted in the trapping of Tfn in to ARF6-positive endosomes similar to ARF6_T27N and prevented 
recycling of Tfn to the plasma membrane. AR149 and A-RAF were found in the complex with ARF6 
(Fig. 4-7B and 4-17A), which indicates a possible mechanism for their effect on Tfn recycling. 
The first suggestion for a role of A-RAF in endocytosis was obtained by screening work. A-RAF 
kinase was proposed as a potential regulator of caveolae-dependent endocytosis (Pelkmans et al., 
2005). Further analysis of A-RAF contribution in caveolae-mediated endocytosis showed in siRNA 
silencing experiments that A-RAF stabilizes the structure of caveolae (Pelkmans and Zerial, 2005). 
Our data demonstrate for the first time A-RAF localization to the endosomes. Moreover, our finding 
suggests a requirement of A-RAF kinase activity in a descrete step of vesicular trafficking: transfer of 
cargo from tubular recycling endosomes to TGN-associated recycling compartment. 
Our work postulates a broad role of A-RAF in regulation of endocytosis, including inhibitory effect 
of A-RAF splicing isoforms, DA-RAF1 and DA-RAF2 (Yokoyama et al., 2007), on vesicular 
trafficking. In fact, the unique localisation of DA-RAF2/AR149 to the tubular vesicular endosomes 
suggests local inhibition of mitogenic signalling, attached to endosomes by A-RAF, on the level of 
recycling compartment. This conclusion differ from a suggestion of general inhibitory effect of DA-
RAF on mitogenic signalling (Yokoyama et al., 2007).  
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Based on intrinsic localisation of endogenous A-RAF (discussed in Chapter 5.5), we conclude 
that A-RAF functionally associates with endosomes shuttling from plasma membrane by short-
distance (actin-dependent) trafficking to the tip of microtubule and then by the long-distance 
(microtubule-associated) vesicular trafficking to recycling compartment. At this level, the A-RAF 
kinase activity is essential for the transfer of Tfn-positives endosomes to TGN-associated recycling 
compartment and subsequent recycling to the plasma membrane. 
 
5.7 A-RAF and AR149 regulate ARF6 activation 
Cooperation of ARF6 and ERK was notified in some earlier reports. One work focused on ARF6-
ERK epistasis, could not decide about direction of co-regulation of these proteins and proposed that 
ERK functions upstream and downstream of ARF6 (Robertson et al., 2006). Some other reports 
asserted that active ARF6 cause increased pERK level during epithelial tubule development (Tushir 
and D'Souza-Schorey, 2007) or glioma cell invasion (Li et al., 2006) and concluded that ARF6 
functions upstream of ERK. Till now, the exact mechanism and epistasis of ARF6 and ERK is an 
unsolved question. Based on our results, we clearly define the epistatic direction of A-RAF-ARF6 
cooperation and suggest the following sequence of event: A-RAF-driven ERK activation results in 
activation of ARF6. The reason for earlier obscurities seems to be involvement of ARF6 GTPase in 
mitogen receptor internalisation and its subsequent, indirect influence on receptor signalling. It is 
known that constitutively active (GTP-bound) ARF6 localizes to the plasma membrane and 
prevents the internalisation of activated receptors(D'Souza-Schorey et al., 1995), which can result in 
sustained signalling from mitogen receptor to ERK. However, the sole fact that increased level of 
active ERK could be detected in cells expressing constitutively active ARF6 does not established 
ERK as a downstream effector of ARF6. Our biochemical experiments reveal not only epistatic 
direction, but also the fine details of ARF6 regulation by ERK. ERK, regulating ARF6 activity, 
should be phosphorylated locally on recycling endosomes by A-RAF. Additionally, we identified a 
possible target of ERK activity, the GEF of ARF6, EFA6 (Fig.4-17D, F). The analysis of EFA6 
sequence by NetPhos software reveals a number of potential ERK phosphorylation sites that 
suggest EFA6 could be a substrate for ERK. Moreover, we found a potential ERK binding site in 
EFA6A, amino acid sequence FXFP, which occurs in KSR and A-RAF too, but not in C-and B-
RAF (Jacobs et al., 1999). 
In general, crosstalk between signal transduction and endocytosis seems to be of physiological 
necessity (Polo and Di Fiore, 2006; Sorkin and Von Zastrow, 2002).  There is some evidence that 
the MAP kinase signalling is on the one hand involved in endocytosis regulation and on the other 
hand is dependent on that. For example, it was shown, that activated RAS can facilitate mitogen 
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receptor internalisation by activation of RIN, a GEF factor for RAB5 (Huang et al., 2001). Another 
potential player in cross talk is ERK, which, curiously, was originally named microtubule-
associated protein-2 kinase which phosphorylates microtubule-bound protein-2 in vitro (Ray and 
Sturgill, 1987). Nevertheless, no confirmation of ERK association with microtubule in proliferating 
cells has been published. Therefore this name was rejected by the scientific community as 
misleading. Only later, the ERK association with microtubule in vivo was documented (Reszka et 
al., 1995) and then, showed to control orientation of actin fibers and microtubule to the plasma 
membrane (Reszka et al., 1997). Indeed, at least part of mitogenic signalling is shown to take place 
on the endosomes. For example, MEK partner, MP1, which is associated with p14, a protein tightly 
associated with late endosomes/lysosomes, was shown to target MEK to late endosomes and to be 
crucial for ERK activation in response to EGF (Teis et al., 2006; Teis et al., 2002). In the nervous 
system ERK was shown to be essential for synaptic plasticity by regulation of 
endocytosis/exocytosis of NMDA and AMPA receptors (reviewed in (Samuels et al., 2009)). 
Interestingly, ARF6 was also found to regulate synaptic plasticity, where EFA6 is its main GEF-
factor (rewieved in (Jaworski, 2007)). In summary, our data begin to bring these separated pieces of 
evidence together like fragments of a puzzle and propose a new link between mitogenic cascade and 
ARF6-dependent endocytosis. 
 
5.8 Model of A-RAF function in vesicular trafficking 
Discovery of A-RAF localisation on the endosomes, its specific interaction with ARF6 and 
regulation of ARF6 activity through EFA6, led us to propose a new model of A-RAF function 
shown in Fig. 5-1. Activation of growth factor receptor leads to conformational changes and 
subsequently to activation of RAS. In this activated state, RAS·GTP recruits RAF proteins at the 
plasma membrane, which triggers a number of phosphorylation events, activating RAF proteins and 
causing the formation of  MAPK signalling module on the plasma membrane. All three RAF 
isoforms are activated successively and shift the mitogenic signalling to different intracellular 
compartments. A-RAF has prolonged kinase activity (Wixler et al., 1996) due to positive feedback 
phosphorylation by ERK (Baljuls et al., 2008), whereas C-RAF is readily inhibited by negative 
ERK feedback phosphorylation (Dougherty et al., 2005) (Hekman et al., 2005). 
Because of its intrinsic interaction with membrane lipids (see chapter 5.3), A-RAF localizes to 
PtdIns(4,5)P2-rich membrane domains on the plasma membrane and on the endosomes.  Here A-
RAF is in immediate proximity to ARF6 GTPase and, probably, to its GEF-factor - EFA6. A-RAF- 
driven mitogenic cascade on the endosomes is activated with delay to initial receptor stimulation, 
because it prior production of ERK and endocytosis of the activated receptors. The endosomally 
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located cascade activates ARF6. This activation is mediated by EFA6, which is activated by 
phosphorylation with ERK. The A-RAF inhibitory splicing isoform, DA-RAF/AR149, localizes to 
tubular recycling endosomes, where it blocks the ERK phosphorylation and, subsequent by the 
ERK effect on ARF6 activation.  
Our findings on A-RAF regulation of endosome recycling pave the way for explaining the 
phenotype of A-RAF knock-out mice, which display a number of neurological defects: ataxia, 
muscle rigidity and megacolon (reminder on Hirschsprung's disease with aganglionic ethiology). 
This phenotype still awaits elucidation of molecular/cellular mechanisms underlying it. Excitingly, 
A-RAF, ARF6 and EFA6 are strongly expressed in the Purkinje cells of mouse cerebellum (Luckett 
et al., 2000) (Matsuya et al., 2005). Moreover, tissue distribution of A-RAF splicing isoforms DA-
RAF1,2 shows a profile different from that of wild type A-RAF with strong expression in the 
mouse brain (Yokoyama et al., 2007). The meaning of these facts will be first clarified after 
physiological and/or ultrastructural analysis of synapses in knock-out mice. All in all, discovery of 
A-RAF function in vesicle recycling is compatible with a role of A-RAF in synaptic plasticity.  
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Figure 5-1.  Model of A-RAF and AR149/DA-RAF function in regulation of endocytosis. ** 
Activation of growth factor receptor (here EGF receptor) leads to RAS-mediated activation of RAF kinases. 
RAF isoforms sort into different membrane microdomains, such as A-RAF into PtdIns(4,5)P2 rich domains. 
Activated Erk has opposing effects on A-RAF and C-RAF. Whereas A-RAF is activated, C-RAF becomes 
inactivated by feedback phosphorylation. A-RAF bound to PtdIns(4,5)P2 rich membranes continues to signal 
on endosomes leading to ARF6 activation. AR149/DA-RAF locates to recycling endosomes and blocks Erk 
activation in this compartment. See the main text for details 
EE - early endosome, RC – recycling compartment, PM – plasma membrane. Red arrows indicate positive 
regulation of the process.  Pale brown color indicates PtdIns(4,5)P2 rich membrane microdomains. 
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